And Genetic Testing for All . . . The Coming Revolution in NonInvasive Prenatal Genetic Testing by King, Jaime S.
University of California, Hastings College of the Law
UC Hastings Scholarship Repository
Faculty Scholarship
2011
And Genetic Testing for All . . . The Coming
Revolution in NonInvasive Prenatal Genetic
Testing
Jaime S. King
UC Hastings College of the Law, kingja@uchastings.edu
Follow this and additional works at: http://repository.uchastings.edu/faculty_scholarship
This Article is brought to you for free and open access by UC Hastings Scholarship Repository. It has been accepted for inclusion in Faculty Scholarship
by an authorized administrator of UC Hastings Scholarship Repository. For more information, please contact marcusc@uchastings.edu.
Recommended Citation
Jaime S. King, And Genetic Testing for All . . . The Coming Revolution in NonInvasive Prenatal Genetic Testing, 42 Rutgers Law Journal 599
(2011).
Available at: http://repository.uchastings.edu/faculty_scholarship/1101
AND GENETIC TESTING FOR ALL...
THE COMING REVOLUTION IN NON-INVASIVE
PRENATAL GENETIC TESTING
Jaime S. King*
For thousands of years, expecting parents have daydreamed of being able
to know about their children before their birth. Over the last thirty years,
reproductive genetics and assisted reproductive technology (ART) have
made significant strides toward fulfilling this desire. A steady stream of
technical advances including prenatal screening, invasive prenatal diagnosis,
sperm and egg donation, sperm sorting for gender selection, in vitro
fertilization, and preimplantation genetic diagnosis have sought to give
parents more information about and control over their reproductive practices.
However, each of these technologies has significant drawbacks that limit its
use to either a very small population or a small number of conditions. As a
result, their overall impact on reproduction has been equally limited.'
Everything is about to change. Scientists have recently discovered a way
to provide diagnostic genetic information to pregnant women early in
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1. Although, non-medical sex selection through sperm sorting, ultrasound sex
determination and preimplantation genetic diagnosis have had a significant impact on the male
to female ratio in society in countries like India and China with strong preferences for male
offspring.
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pregnancy through a blood test, which poses no risk to the fetus. Researchers
have long sought a test that offers non-invasive prenatal genetic diagnosis
(NIPD). NIPD was finally achieved by capturing and analyzing fragments of
fetal DNA, known as cell-free fetal DNA (cffDNA), found in the pregnant
woman's bloodstream. 2 By examining cffDNA, scientists have been able to
detect a wide range of known genetic and chromosomal conditions with a
high degree of accuracy. 3 Existing cffDNA clinical applications include
testing for Down syndrome, trisomy 13, trisomy 18, fetal sex, and potential
pregnancy complications, such as an Rh factor incompatibility. 4 However,
the future promises testing for single gene disorders and more complex
genetic diseases and conditions, culminating in the possibility of conducting
genome wide analysis of the complete fetal genome using cffDNA from a
maternal blood sample.5 In December 2010, two separate laboratories
demonstrated that a full genome-wide analysis of the fetus could be
performed from a sample of the mother's blood, making prenatal testing for
any diagnosable genetic condition or predisposition possible in the future.
6
2. Y.M. Dennis Lo et al., Presence of Fetal DNA in Maternal Plasma and Serum, 350
LANCET 485, 485-87 (1997) [hereinafter Lo et al., Presence of Fetal DNA]; Y.M.D. Lo, Non-
invasive Prenatal Detection of Fetal Chromosomal Aneuploidies by Maternal Plasma Nucleic
Acid Analysis: A Review of the Current State of the Art, 116 BRIT. J. OBSTETRICS &
GYNAECOLOGY 152, 152 (2009) [hereinafter Lo, Non-invasive Prenatal Detection].
3. Id; Y.M. Dennis Lo et al., Maternal Plasma DNA Sequencing Reveals the Genome-
Wide Genetic and Mutational Profile of the Fetus, 2 Sci. TRANSLATIONAL MED. 1 (2010);
Mei-Chi Cheung et al., Prenatal Diagnosis of Sickle Cell Anemia and Thalassemia by
Analysis of Fetal Cells in Maternal Blood, 14 NATURE GENETICS 264, 264-68 (1996); H.
Christina Fan et al., Non-invasive Diagnosis of Fetal Aneuploidy by Shotgun Sequencing DNA
From Maternal Blood, 105 PROC. NATL. ACAD. SCI. 16266, 16266 (2008). These tests are able
to detect the genetic or chromosomal variables associated with the disorder with a high degree
of accuracy. However, other factors like penetrance, gene-gene, and gene-environment
interactions may affect the likelihood of the child manifesting the physical symptoms of
disease.
4. Sequenom CMM's MaterniT21 PLUS Test Expands Current Prenatal Testing
Offering, SEQUENOM.COM (Feb. 8, 2012) http://sequenom.investorroom.com
/index.php?s=43&item=326; Verinata Health Announces Presentation and Publication of
Top-Line Clinical Validation Study Results for its verifTM Non-Invasive Prenatal Test,
VERINATA.COM, http://www.verinata.com/news/non-invasive-prenatal-test/ (last visited Mar.
20, 2012); Caroline F. Wright & Hillary Burton, The Use of Cell-free Fetal Nucleic Acids in
Maternal Blood for Non-invasive Prenatal Diagnosis, 15 HUM. REPRODUCTION UPDATE 139,
142 (2009).
5. Lo et al., supra note 3, at 3; H. Christina Fan & Stephen R. Quake, In Principle
Method for Non-invasive Determination of the Fetal Genome, NATURE PRECEDINGS (Dec. 8,
2010), doi: 10.1038/npre.2010.5373.1.
6. The two laboratories were at Stanford University and the Chinese University of
Hong Kong. The Stanford lab is run by Stephen Quake and commercially associated with
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Manifesting this technological potential will offer prospective parents a
risk-free and relatively inexpensive means to discover an enormous amount
of information about their fetus at a very early point in the pregnancy, which
will be limited only by our knowledge and understanding of genetics. NIPD
using cffDNA is currently offered as early as nine weeks gestation and is less
expensive than current prenatal testing methods.7 Once successfully
commercialized and integrated into practice, NIPD testing for a range of
genetic disorders and conditions is well poised to become the standard of
care, such that it would be routinely offered to all pregnant women.
Without question, the availability of NIPD through the use of cffDNA
testing marks an enormous advance in reproductive genetic testing that will
provide significant benefits to millions of prospective parents, but it does not
come without challenges and complications. NIPD promises to expand our
ability to provide pregnant women with genetic information about their
fetuses, but in many cases, it will not improve our ability to explain the
implications of much of that information in a meaningful way. Often
physicians themselves do not fully understand the results of a genetic test, or
are not well trained in how to communicate those results to patients. Further,
while the majority of existing genetic tests examine disorders that arise from
a mutation in a single gene, the vast majority of heritable conditions and
traits result from the interactions of multiple genes or genes and the
environment. For these conditions, NIPD testing will most likely provide
prospective parents with a series of probabilities that a fetus will have a
specific condition or characteristic. In order for NIPD to truly improve
reproductive decision making, physicians and pregnant women will need
guidance on which tests are appropriate for prenatal use, how to determine
what tests each woman would like to receive, how to interpret the results,
and finally, what options are available after testing. Given NIPD's recent
arrival, we should take steps to address the initial challenges to its integration
into prenatal practice and begin to discuss the broader implications of
widespread NIPD use.
Verinata. The one at the Chinese University of Hong Kong is run by Dennis Lo and
commercially associated with Sequenom. Lo et al., supra note 3, at 1; Fan & Quake, supra
note 5.
7. Sequenom Center for Molecular Medicine Announces Launch of MaterniT21TM
Noninvasive Prenatal Test for Down syndrome, SEQUENOM.COM, (Oct. 17, 2011),
http://sequenom.investorroom.com/index.php?s= 4 3&item=310; Caroline Wright, Cell-Free
Fetal Nucleic Acids for Non-Invasive Prenatal Diagnosis, Report of the UK Expert Working
Group, PHG FOUNDATION, 13, 23 (2009), available at http://www.phgfoundation.org/
download/ffdna/ffDNA report.pdf.
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This Article examines a range of ethical, legal and social implications
associated with introducing NIPD into prenatal practice, and offers a novel
solution to assist physicians and patients in making informed choices
regarding reproductive genetic testing. Part I describes the current status of
NIPD and compares it to existing reproductive genetic testing technologies.
Specifically, Part IA describes the development of cffDNA technology and
its current and potential uses for NIPD, including identification of potential
pregnancy complications, fetal sex determination, chromosomal testing,
testing for single gene disorders, and whole genome screening. Readers less
interested in the technical details of NIPD may wish to move quickly through
IA ahead to Part lB. Part IB argues that NIPD has three features that
differentiate it from existing reproductive genetic testing techniques in ways
that are critical. First, it is non-invasive, and therefore presents no physical
risk to the fetus or mother. Second, NIPD can be offered soon after a woman
discovers she is pregnant. Third, over time it will be comparatively less
expensive than existing prenatal screening and diagnosis techniques.
Part II then explores how a prenatal genetic test with these characteristics
will affect reproductive practices and overall prenatal care. Specifically, the
Article analyzes how NIPD will impact who receives reproductive genetic
tests, what tests are offered, and what role they play in reproductive
decisions. I then argue that the introduction of NIPD into prenatal practice
will significantly increase the number of women who will receive prenatal
genetic diagnosis, broaden the scope of conditions and characteristics they
test for, and offer this information to parents at a point in the pregnancy
when it is more actionable.
Next, Part III addresses the initial challenges of offering a large amount
of information routinely to pregnant women at a very early point in the
pregnancy. As NIPD is integrated into prenatal practice, physicians will face
many challenges regarding what tests to offer and what information to
provide patients. For the most part, these challenges are due to an absence of
regulation and guidance regarding the appropriate uses of prenatal genetic
tests. In addition, NIPD will strain current genetic counseling and informed
consent protocols. The Article argues that a new method of informing
patients about the prenatal genetic tests offered through NIPD is required in
order for physicians to meet their informed consent obligations. It also
discusses the potential emotional and psychological harms that can arise for
women if the informed consent process is not performed appropriately,
causing them to receive diagnostic genetic results that they did not
knowingly want, or worse, that they knowingly did not want. To remedy
these issues, Part III proposes the use of a two-step informed consent process
that offers pregnant women a variety of genetic testing panels. Each panel
[Vol. 42:599
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will consist of multiple genetic conditions with similar salient clinical
features, such as severity of symptoms, age of onset, and likelihood of
contracting the disease. This approach aims to simplify the genetic
counseling requirements, ease the regulatory approval process, and permit
physicians to use advances in informed consent technology, like decision
aids, to improve the decision-making process for both parents and
physicians.
Finally, Part IV will highlight some potential societal issues that may be
raised by the advent of widespread cffDNA testing. Full analysis of the
topics in Part IV is beyond the scope of this Article, but the topics are
mentioned to encourage future discussion, research and writing on the long
term implications of widespread NIPD use.
I. NON-INVASIVE PRENATAL GENETIC DIAGNOSIS
VIA CELL FREE FETAL DNA
A. The Development of NIPD
For the last three decades, scientists have known that whole fetal cells
pass through the placenta into pregnant women's blood.8 This discovery
opened the possibility of obtaining fetal DNA from maternal blood, which
would provide a much sought after non-invasive testing option for
reproductive genetic testing.9 Current methods of diagnostic prenatal genetic
testing carry around a 1 percent risk of fetal miscarriage and can be quite
uncomfortable for the pregnant woman.' 0  However, producing a
commercially viable, non-invasive, prenatal genetic test from fetal cells in
the mother's blood has remained elusive due to technical challenges" n
8. Leonard A. Herzenberg et al., Fetal Cells in the Blood of Pregnant Women:
Detection and Enrichment by Fluorescence-activated Cell Sorting, 76 PROC. NAT'L ACAD.
Sci. USA 1453, 1453-55 (1979); Cheung, supra note 3 at 264-68; Fan et al., supra note 3 at
16266.
9. Cheung, supra note 3 at 264-68.
10. Caroline F. Wright & Lyn S. Chitty, Cell-free Fetal DNA and RNA in Maternal
Blood: Implications for Safer Antenatal Testing, 339 BRIT. MED. J. 161, 161 (2009).
11. Difficulties have occurred on two fronts. First, whole fetal cells are difficult to find
in the mother's blood. See Diana W. Bianchi et al., PCR Quantitation of Fetal Cells in
Maternal Blood in Normal and Aneuploidy Pregnancies, 61 AM. J. HUM. GENETICS 822
(1997); Lo, Non-invasive Prenatal Detection, supra note 2, at 152. Second, while rare, these
cells can live in maternal blood for decades, meaning that a geneticist would not know if the
cell found was from the existing pregnancy or a former one. See Wright & Burton, supra note
4, at 142 (2009). In 2002, a multicenter trial, using the some of the best technology for the
2011]
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Researchers have since found an alternative path to non-invasive testing
using DNA that floats freely in maternal blood. In 1997, Dennis Lo and
colleagues, researchers from The Chinese University of Hong Kong,
discovered that fragments of DNA from a fetus exist outside the cell in the
blood plasma of its mother.12 During pregnancy, this cell-free fetal DNA
(cffDNA) represents anywhere from 3 to 10 percent of the cell free DNA in
the maternal blood stream, with the remaining 90 to 97 percent belonging to
the mother.' 3 Cell-free fetal DNA is typically found in short fragments, 14 and
can be detected as early as four weeks gestation. 15 However, the
concentration of cffDNA increases with gestational age until seven weeks
when it stabilizes at about 10 percent for the remainder of the pregnancy.'6
After the birth, cffDNA clears from the maternal blood within two hours,
ensuring that any fetal DNA detected is from the current fetus.' 7 Over the last
decade, these findings have dramatically changed the landscape with respect
to the possibilities for prenatal genetic diagnosis.'
8
isolation of nucleated fetal cells from maternal blood, reported a sensitivity of only 41.4
percent for the detection of male fetal cells in maternal blood, with a false positive rate of 11.1
percent. D. W. Bianchi et al., Fetal Gender and Aneuploidy Detection Using Fetal Cells in
Maternal Blood: Analysis of NIFTY I Data, 22 PRENATAL DIAGNOSIS 609, 609 (2002).
Sensitivity is the ability of a test to correctly identify positive responses, i.e. the true positive
rate. As a result of this and other similar research findings, scientists have not successfully
commercialized a genetic test based on whole fetal cells in maternal blood.
12. Lo et al., Presence ofFetal DNA, supra note 2, at 485-87.
13. Lo, Non-invasive Prenatal Detection, supra note 2, at 153 (stating that cffDNA
makes up a mean of 3-6 percent of DNA present in maternal plasma); Fan et al., supra note 3,
at 16266 (stating that fetal DNA can constitute up to 10 percent of the total cell free DNA in
the maternal serum); Fiona M. F. Lun et al., Non-invasive Prenatal Diagnosis of Monogenic
Diseases by Digital Size Selection and Relative Mutation Dosage on DNA in Maternal
Plasma, 105 PROC. NATL. ACAD. SCI. 19920, 19920 (2008).
14. K.C. Allen Chan et al., Size Distributions of Maternal and Fetal DNA in Maternal
Plasma, 50 CLINICAL CHEMISTRY 88, 88 (2004).
15. S. Illanes et al., Early Detection of Cell-free Fetal DNA in Maternal Plasma, 83
EARLY HUM. DEV. 563, 565 (2007).
16. Lyndsey Birch et al., Accurate and Robust Quantification of Circulating Fetal and
Total DNA in Maternal Plasma From 5 to 41 Weeks of Gestation, 51 CLINICAL CHEMISTRY
312 (2005).
17. Lo, Non-invasive Prenatal Detection, supra note 2, at 153; Y.M. Dennis Lo et al.,
Rapid Clearance of Fetal DNA From Maternal Plasma, 64 AM. J. HUM. GENETICS 218 (1999).
18. However, the road to producing a commercially viable NIPD test has not been easy.
Four major challenges arose: (1) low concentration of all cell free DNA in blood; (2) total
amount of cell free DNA varies significantly from individual to individual; (3) the ratio of
maternal cell free DNA to cffDNA molecules is high; and, (4) half of the fetal genome is from
the mother. Wright & Burton, supra note 4, at 140. To address these issues, researchers must
purify and isolate cell free DNA from maternal blood plasma and then compare known
[Vol. 42:599
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Initial uses of cffDNA include diagnostic testing for the potential
pregnancy complications (such as an Rh factor incompatibility), sex of the
fetus, single gene disorders, and chromosomal disorders (including Down
syndrome).' 9 In the future, researchers plan to develop tests for more
complex genetic diseases and conditions, culminating in the possibility of
conducting genome wide analysis of the complete fetal genome using
cffDNA from a maternal blood sample.20 Realizing this potential will offer
prospective parents an enormous amount of information about their fetus,
limited only by our understanding of genetics. Each of these uses will be
discussed in more depth below.
1. Pregnancy Complications
Cell-free fetal DNA testing can diagnose two kinds of conditions during
pregnancy that affect maternal-fetal wellbeing: abnormal placental
functioning and fetal Rhesus blood group incompatibility. 21 First, elevated
levels of cffDNA in the mother's blood can signal an increased risk of a
variety of pregnancy complications, especially those associated with
abnormal formation or function of the placenta.2 2 Such complications include
preeclampsia (the leading cause of premature birth and the most common
dangerous complication of childbirth), preterm labor, severe morning
sickness, intrauterine growth restriction, feto-maternal hemorrhage, and
polyhydramnios (too much amniotic fluid).2 3 Identifying these complications
early in pregnancy, even before symptoms arise, can improve prenatal
healthcare outcomes for both the mother and child.
genetic markers and polymorphisms to differentiate between maternal cell free DNA and
cffDNA. Id. A number of different methods have been used to differentiate between maternal
and fetal DNA including real-time quantitative PCR, nested PCR, digital PCR, gel
electrophoresis, and mass spectrometry. Id. at 141. The ratio of maternal to fetal cell free
DNA can also be improved by using standard size fractionation or mass spectrometry to select
smaller DNA fragments that are more likely to have come from the fetus. Id.
19. Wright & Burton, supra note 4, at 142.
20. Lo, Non-invasive Prenatal Detection, supra note 2; Fan & Quake, supra note 5.
21. Wright & Burton, supra note 4, at 144.
22. Id. at 145.
23. Id.; S. Hahn et al., Fetal Cells and Cell Free Fetal Nucleic in Maternal Blood: New
Tools to Study Abnormal Placentation?, 26 PLACENTA 515 (2005). Although researchers have
discussed using cffDNA concentration as another biomarker during pregnancy to detect
preeclampsia in asymptomatic patients, due to cffDNA's constant concentration fluctuations,
challenges with diagnostic accuracy must be overcome prior to widespread use of a screening
test. Wright & Burton, supra note 4, at 145.
2011]
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Second, the availability of NIPD through cffDNA testing can eliminate
unnecessary treatments in many pregnant women. For example, cffDNA
testing can provide information on the Rh status of a fetus in a non-invasive
manner. The presence or absence of Rhesus D (RhD) antigens on the surface
of blood cells determines the positive or negative designation in an
individual's blood type." Problems arise when Rh-positive fetal blood cells
carrying paternally inherited RhD antigens enter an Rh-negative mother's
blood stream during delivery, which does not have the RhD antigens. In that
case, the Rh-negative mother will produce an immune response against the
"foreign" fetus.25 This immune response will not harm the first fetus during
delivery. But if another child is conceived with RhD antigens, maternal
antibodies can cross the placenta and attack the new fetus' red blood cells,
which can be fatal to the fetus. 26 Rh incompatibility can be treated
prophylactically with anti-D antibodies during pregnancy. Unfortunately,
current methods of prenatal diagnosis are invasive and have additional risks
beyond the 1 percent increase in miscarriage when testing for RhD status,
27
making it risky to identify an at-risk pregnancy. As a result, all women with
prior Rh incompatible children are put on prophylactic anti-D antibodies
during their subsequent pregnancies. 28 Cell-free fetal DNA provides a
powerful tool to safely and easily identify only those fetuses with an
incompatible Rh status, thereby eliminating unnecessary treatment of all
women with a prior Rh incompatible pregnancy. 29 Rh status testing is one of
the first commercialized clinical applications of cffDNA testing.
2. Fetal Sex Determination
Geneticists first used cffDNA to detect major similarities or differences
between the fetal and maternal DNA, such as the sex of the fetus.3 ° In the
24. Wright & Burton, supra note 4, at 145.
25. Am. College of Obstetricians and Gynecologists, Practice Bulletin No. 75:
management of alloimmunization, 108 OBSTETRICS & GYNECOLOGY 457-64 (2006).
26. Wright & Burton, supra note 4, at 144.
27. Richard B. Smith et al., The Obstetrician's View: Ethical and Societal Implications
of Non-Invasive Prenatal Diagnosis, 26 PRENATAL DIAGNOSIS 631, 631 (2006). The additional
risks include feto-maternal hemorrhage and conversion of mild to severe rhesus hemolytic
disease. Id.
28. Wright & Chitty, supra note 10, at 162.
29. Wright & Burton, supra note 4, at 144; Ossie Geifman-Holzman et al., Diagnostic
Accuracy of Non-invasive Fetal Rh Genotyping From Maternal Blood-A Meta-analysis, 195
AM. J. OBSTETRICS & GYNECOLOGY 1163, 1164 (2006).
30. Lo, Non-invasive Prenatal Detection, supra note 2, at 153.
[Vol. 42:599
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case of sex determination, the presence or absence of a Y chromosome
reveals fetal sex. If cffDNA from the Y chromosome is present the fetus is
male, if not, female. In families with a history of X-linked disorders, such as
Duchenne/Becker Muscular Dystrophy, sex determination provides a
powerful tool for identifying male fetuses at risk for the X-linked disease.
31
Of course, scientists can also use such testing capability to determine the sex
of the fetus for non-medical purposes, such as family balancing or parental
preference. A handful of biotechnology companies already offer cffDNA
testing for fetal sex determination on a direct-to-consumer (DTC) basis. 3
2
3. Single Gene Disorders
Researchers can also use cffDNA to detect any paternally inherited or
spontaneously occurring genetic mutations, which would not be present in
the mother's DNA.33
Thousands of genetic diseases result from a mutation in a single gene,
often at a single locus. 34 Due to the fragmented nature of cffDNA, detecting
both large-scale mutations and single point mutations has been very
challenging and generally limited to only the detection of alleles not present
in the mother.35 However, researchers are making rapid progress in this area.
For autosomal dominant disorders, like Huntington's disease 36  and
Achondroplasia, 37 in which receiving one copy of the disease allele is
31. If a mother carries an X-linked disorder, meaning that she has one normal X
chromosome and one mutated X chromosome, there is a 50 percent chance that a male fetus
will have the disorder because males only have one X chromosome. About X-Linked
Disorders, CENTERS FOR DISEASE CONTROL AND PREVENTION (Aug. 28, 2006),
http://www.cdc.gov/ncbdddlsinglegene/x-link.htm.
32. See Wright, supra note 7, at 22 (listing Acu-Gen Baby Gender Mentor, Pink And
Blue Early DNA Gender Test, DNA Plus fetal test and paternity test).
33. Lo, Non-invasive Prenatal Detection, supra note 2, at 153.
34. Wright & Burton, supra note 4, at 143.
35. Id.
36. Huntington's disease is a genetic disease caused by a mutation on chromosome 4
that causes neurological degeneration. The typical age of onset is in the 30s or 40s and
common symptoms include restlessness, facial movements, unsteady gait, quick sudden
jerking movement of limbs, loss of memory, loss of judgment, personality changes and
disorientation. Huntington's Disease, MEDLINEPLUS (June 24, 2009), http://www.nlm.nih.gov/
medlineplus/ency/article/000770.htm.
37. Achondroplasia is a genetic disorder of bone growth that results in abnormal body
proportions such as short arms and legs, with a relatively normal size torso. Children with
achondroplasia are likely to have poor muscle-tone, leading to developmental delays in
crawling, walking and other motor skills. Achondroplasia, MARCH OF DIMES (Sept. 2008),
http://www.marchofdimes.com/Baby/birthdefectsachondroplasia.html.
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sufficient to inherit the disease, cffDNA testing can be diagnostic if the
father, but not the mother, has the disease allele. However, creating tests for
autosomal recessive disorders, such as cystic fibrosis 39 and Tay Sachs, 40 in
which the fetus must receive a disease allele from both the mother and father
to inherit the disease, proved more challenging. Initially, cffDNA testing
could be used to diagnose the fetus only if the mother had the recessive
disease, because only the single recessive allele would be present in the
maternal blood stream. 41 For the more common case, where the mother was a
carrier, with one normal allele and one disease allele, cffDNA testing could
42not be used to diagnose the fetus.
However, a new approach, known as digital relative mutation dosage
(digital RMD), offers a possible method for geneticists to diagnose a fetus
43with an autosomal recessive disorder, even if its mother was a carrier.
Digital RMD first divides all cell free DNA in the maternal blood into groups
of normal and disease alleles. 44 Geneticists then examine whether the
amounts of normal and disease alleles in the maternal plasma sample are in
allelic balance or imbalance.45 If the ratio of normal and disease alleles is
balanced, then geneticists expect the fetus to be a carrier of the disease, like
its mother. If the alleles are imbalanced, the disease allele is either over- or
underrepresented. Overrepresentation of the disease allele indicates the fetus
has two copies of the disease allele and therefore will have the disease.
46
Alternatively, underrepresentation indicates that the fetus has two copies of
38. Lun, supranote 13, at 19920.
39. Cystic fibrosis is a genetic disease of the mucus glands that affects numerous
systems in the body. Symptoms of the disorder include progressive deterioration of the
respiratory system and chronic digestive problems. Cystic Fibrosis, GENETICS HOME
REFERENCE (Jan. 2008), http://ghr.nlm.nih.gov/condition/cystic-fibrosis.
40. Tay Sachs is a rare genetic disorder that causes progressive destruction of the nerve
cells in the brain and spinal cord. As the disease progresses, children experience seizures,
vision and hearing loss, intellectual disability and paralysis. Tay Sachs Disease, GENETICS
HOME REFERENCE (Sept. 2008), http://ghr.nlm.nih.gov/condition/tay-sachs-disease.
41. Caroline Wright, Advances in Non-Invasive Prenatal Diagnosis of Recessive
Diseases, PHG FOUNDATION, available at http://www.phgfoundation.org/news/4422/.
42. Lun, supra note 13, at 19920. The mother's blood will have high levels cffDNA
with both the wild-type and mutated allele because the mother carries both alleles. Originally,
researchers could not distinguish which alleles came from the fetus and which ones came from
the mother, unless the fetus carried a paternally derived mutation.
43. ld. at 19921.
44. Id.
45. Id.
46. Id.
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the normal allele and will not have the disease nor be a carrier.47 Scientists
have recently furthered this method by using known maternal haplotypes
(based on nearby SNP alleles on the same chromosome) to analyze the
relative haplotype dosage to provide significantly more information on the
fetal genome. 48 At high enough throughput volume, comparing overall ratios
of cell free DNA in maternal blood with certain characteristics offers a
promising avenue for developing diagnostic reproductive genetic tests using
cffDNA.
4. Chromosomal Abnormalities
While identifying variations between maternal and fetal DNA has proven
effective for detecting conditions associated with a single gene, using these
variations to diagnose diseases associated with an entire chromosome, such
as Down syndrome, 49 has been challenging.50 However, researchers have
successfully created testing protocols that examine very small differences in
the ratios of the amount of cffDNA from each chromosome present in
maternal blood serum. Dennis Lo and colleagues isolated and amplified
DNA regions on the chromosomes of interest and then compared the overall
dosage of the chromosome of interest to the dosage of a reference
47. Id.
48. Lo et al., supra note 3, at 4.
49. Down syndrome results from having an extra copy of the 21st chromosome.
Common symptoms of Down syndrome include intellectual impairment, severe learning
disabilities, and shortened lifespan resulting from long term health problems, such as heart
disease. The incidence of Down syndrome increases with maternal age from about .07 percent
at age twenty to 1 percent at age forty. See Down syndrome, US NAT'L LIBRARY HEALTH,
(Oct. 18, 2010), http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001992/; see also Down
syndrome, NAT'L INST. OF HEALTH (Feb. 17, 2012), http://www.nichd.nih.gov/
health/topics/downsyndrome.cfm.
50. Fan & Quake, supra note 5, at 1. Researchers have struggled to detect aneuploidies
(abnormal numbers of chromosomes) using cffDNA in maternal blood plasma because they
must selectively target a number of fetal DNA sequences on specific chromosomes and then
find differences in the ratio of genetic markers for each chromosome, rather than simply
differences in the DNA sequence between the mother and fetus. Fan & Quake, supra note 5, at
1; Lo, Non-invasive Prenatal Detection, supra note 2, at 153 (discussing methods to do so
using placental mRNA, epigenetic markers, and digital PCR). See also, Y.M. Dennis Lo et al.,
Plasma Placental RNA A llelic Ratio Permits Non-invasive Prenatal Chromosomal A neuploidy
Detection, 13 NATURE MEDICINE 218 (2007); Ravinder Dhallan et al., A Non-invasive Testfor
Prenatal Diagnosis Based on Fetal DNA Present in Maternal Blood: A Preliminary Study,
369 LANCET 474 (2007).
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chromosome. 51 As with genetic alleles, even small increases or decreases in
the expected dosage of a particular chromosome can indicate aneuploidy, an
abnormal number of chromosomes, in the fetus. Steve Quake and colleagues
from Stanford University quantified the number of DNA sequences that
came from each chromosome and then analyzed the results for over- and
underrepresentation of a particular chromosome in the fetus.52 Both studies
demonstrated a high level of accuracy in detecting Down syndrome, in which
a fetus has three copies of the twenty-first chromosome.
53
Initially, NIPD testing for Down syndrome will be used to rule out Down
syndrome in pregnancies that have screened high risk for the disorder,
thereby greatly limiting the number of women that would require invasive
prenatal diagnosis (IPD) in the form of an amniocentesis or CVS. 54 Current
screening techniques have false positive rates of about 5 percent, and all of
those women are offered IPD. NIPD can rule out Down syndrome in 98
percent of those cases, meaning that only 0.1 percent of all pregnant women
would need a referral for IPD to detect Down syndrome.55 As the cost of
NIPD decreases, researchers anticipate that it could become the first tier
screen offered to all women for Down syndrome and other chromosomal
abnormalities.56
5. Whole Genome Sequencing
Lo and Quake have now moved beyond single gene testing and
chromosomal analysis to whole genome sequencing of the fetus from a
maternal blood sample. In a proof-of-principle paper published December 8,
2010, Dennis Lo and colleagues mapped an entire fetal genome from
cffDNA present in maternal blood plasma.57 They also demonstrated that
51. Y.M. Dennis Lo et al., Digital PCR for the Molecular Detection of Fetal
Chromosomal Aneuploidy, 104 PROC. NATL. ACAD. SCI. 13116, 13117 (2007). Lo and
colleagues used digital PCR to isolate and amplify the DNA sequences of interest.
52. Fan & Quake, supra note 5, at 1. Quake used simultaneous shotgun sequencing, a
method for sequencing long strands of DNA. It gets its name from the similarity between the
method and the rapidly-expanding, quasi-random firing pattern of a shotgun.
53. Id. at 2; see also Rossa W.K. Chiu et al., Non-Invasive Prenatal Assessment of
Trisomy 21 by Multiplexed Maternal Plasma DNA Sequencing: Large Scale Validity Study,
342 BRIT. MED. J. 7401, 7407 (2011), available at http://www.bmj.com
/content/342/bmj.c740. This study also revealed a high level of accuracy at detecting other
forms of aneuploidy, including Trisomy 18 (Edward Syndrome) and Trisomy 13 (T13).
54. Chiu et al., supra note 53, at 7-8.
55. Id.
56. Id.
57. Lo et al., supra note 3, at 9.
[Vol. 42:599
AND GENETIC TESTING FOR ALL
cffDNA from all regions of the fetal genome was present in the maternal
58blood in a constant relative proportion to maternal cell-free DNA. Stephen
Quake and colleagues used data known about the parents' DNA and the
relative frequency of those sequences in the cell free DNA blood sample to
help identify which DNA sequences were inherited from each parent, and
therefore the genotype of the fetus. 59 These discoveries mean that the entire
fetal genome could be analyzed from a non-invasive blood test and the
genotype of the parents.60 Such a test could offer prospective parents
information on inherited genetic conditions as well as spontaneous mutations
in the fetal genome. 61 Lo stated that the only limitations on this form of fetal
genetic analysis are the depth of sequencing available and the resolution of
the parental genetic maps.62 Over time, sequencing technology should
improve and the cost should continue to drop, easing access to whole
genome sequencing for both parental and fetal genomes. 63 Before genome-
wide analysis becomes available, Lo and colleagues suggest that this
technology may be used for targeted sequencing approaches to test for
multiple disease-related regions at one time, which would greatly reduce the
cost of prenatal testing for multiple conditions.
64
Currently, NIPD is only commercially available to test for Down
syndrome, Trisomy 13, Trisomy 18, RhD status and fetal sex. The
availability of NIPD testing for a variety of known genetic diseases,
conditions and predispositions is likely to slowly accelerate over the next
decade.66 Beyond diseases caused by chromosomal abnormality, fetal sex
58. Id.
59. Fan & Quake, supra note 5.
60. Id.; see also Lo et al., supra note 3, at 9.
61. Fan & Quake, supra note 5.
62. Id.
63. Id.
64. Lo et al., supra note 3, at 10.
65. Lauren C. Sayres & Mildred K. Cho, Cell-Free Fetal Nucleic Acid Testing: A
Review of the Technology and its Applications, OBSTETRICAL AND GYNECOLOGICAL SURVEY
7-9 (accepted for publication 2011 and on file with author). See generally, DNA Fetal Gender
Determination, CTR. FOR MED. GENETICS, http://www.geneticstesting.com
/gendertest/gendertest.htm (last visited March 16, 2012); Fetal cell/DNA Prenatal Gender
Test, DNAPLUS.COM, http://www.dnaplus.com/fetal-cellprenatalgedertest.htm,(ast
visited March 16, 2012); Early DNA Gender Predicting Test: Boy or Girl?,
TELLMEPINKORBLUE.COM, http://www.tellmepinkorblue.com/Gender-Testing-Boy-Girl.php
(last visited March 16, 2012); Prenatal Gender Testing on Maternal Blood: Y-Chromosome
Detection, PRENATAL GENETICS CTR., http://www.prenatalgeneticscenter.com/gender-intro.asp
(last visited March 16, 2012); Wright, supra note 7; SEQUENOM, supra note 4.
66. Wright & Chitty, supra note 10, at 164.
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and Mendelian genetic diseases, NIPD may one day also be able to offer
parents full analysis of their fetus' entire genome.
67
B. Is There Anything New Here?
The fact that NIPD offers a new form of prenatal genetic testing does not
guarantee a revolution in reproductive practices. Reproductive fetal genetic
testing has been possible for over forty years, 68 but has not yet penetrated
into the core of society as deeply as predicted in Aldous Huxley's Brave New
World or the 1990s science fiction film, Gattaca.69 In fact, in 2009,
physicians in the United States performed IPD on less than 2 percent of all
pregnancies. 70 However, three features of cffDNA testing distinguish it from
current forms of reproductive genetic testing in ways that are critical. First,
the testing is non-invasive. Second, it is offered early in the pregnancy, and
third, it will be less expensive. As a result, cffDNA testing has the potential
to eliminate many of the existing obstacles to diagnostic reproductive genetic
testing and in doing so dramatically expand the volume of pregnant women
receiving prenatal diagnosis and increase the scope of genetic information
for which they are willing to test. And that would be revolutionary.
1. Current Prenatal Genetic Testing
The benefits of cffDNA testing are best understood in comparison to
current prenatal and preimplantation genetic testing techniques. Currently,
pregnant women take very different paths with respect to prenatal genetic
testing. Some women know that they do not wish to receive any genetic
information about their fetus, therefore they will decline both prenatal
genetic screening, which will provide them with probabilistic information
(e.g., 1 in 200 or 1 in 5) on whether their child will have a specific genetic
disorder, and invasive prenatal diagnosis, which will provide them with
diagnostic information on whether their child has the disorder (e.g., positive
or negative). Other women know that they definitely want diagnostic
information as early as possible and are willing to undergo an invasive test
67. Lo et al., supra note 3, at 9.
68. Joseph Woo, A SHORT HISTORY OF AMNIOCENTESIS, FETOSCOPY, AND CHORIONIC
VILLUS SAMPLING, http://www.ob-ultrasound.net/amniocentesis.html.
69. See ALDOUs HUXLEY, BRAVE NEW WORLD (Harper & Brothers 1932); GAYrACA
(Columbia Pictures Corp. 1997).
70. Henry T. Greely, Get Ready for the Flood of Fetal Genetic Screening, 469 NATURE
289, 289 (2011).
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with a slight risk of miscarriage to receive it. Frequently, these women either
have a family history of a genetic disorder or they are at advanced maternal
age (over thirty-five), which increases the risk of Down syndrome and other
disorders. Such women commonly receive IPD in the form of chorionic
villus sampling (CVS) between ten and fourteen weeks gestation.71 In
general, women with strong opinions either against screening or for
immediate invasive diagnostic testing tend to be in the minority.
Most pregnant women elect to have prenatal genetic screening to
determine whether their fetus is at elevated risk for a specific disorder, and
then, if so, make a decision regarding diagnostic prenatal testing.72 Prenatal
genetic screening can include anything from a single blood test in the second
trimester (fifteen to twenty weeks) to a series of tests-a blood test between
ten and thirteen weeks, an ultrasound between eleven and thirteen weeks, and
another blood test between fifteen and twenty weeks.73 The more information
gathered during the screening process, the more accurate the screening
results. Currently, prenatal genetic screening offers prospective parents risk
information for open neural tube defects, abdominal wall defects, certain
genetic diseases, such as Smith-Lemli-Optiz syndrome, and chromosomal
abnormalities, such as Down syndrome. 74 Both the blood tests and the
ultrasound have limitations. The blood tests only provide information on the
probability that the fetus will be affected based on certain markers in the
blood, which can often be difficult to interpret for parents and providers, and
ultrasound only detects physical anomalies.75 If the fetus screens positive for
any of these conditions, the pregnant woman must decide whether to wait
until the fetus is born to know if it has a disorder, or undergo another form of
IPD, known as amniocentesis, 76 to provide diagnostic information about the
71. THE CALIFORNIA PRENATAL SCREENING PROGRAM, RESULTS FOR SCREENING IN THE
FIRST TRIMESTER-THE RESULT OF YOUR SCREENING TEST IS: SCREEN POSITIVE FOR DOWN
SYNDROME 5 (California Department of Public Health ed., 2009). CVS is an invasive
procedure that uses a needle or a tube inserted through the cervix to remove fetal cells from
the placenta for genetic testing.
72. Laura L. Jelliffe-Pawlowski et al., Using Second Trimester Ultrasound and
Maternal Serum Biomarker Data to Help Detect Congenital Heart Defects in Pregnancies
with Positive Triple-marker Screening Results, 146 AM. J. HUM. GENETICS 2455, 2456 (2008).
73. Prenatal Screening Program, CALIF. DEPARTMENT OF PUBLIC HEALTH (2010),
http://www.cdph.ca.gov/programs/pns/Pages/default.aspx.
74. Id.
75. Ainsley J. Newson, Ethical Aspects Arising from Non-Invasive Fetal Diagnosis, 13
SEMINARS IN FETAL & NEONATAL MED. 103, 103 (2008).
76. THE CALIFORNIA PRENATAL SCREENING PROGRAM, supra note 71, at 7.
Amniocentesis involves collecting the fetal cells needed for testing by inserting a needle
through the abdominal wall to remove a small amount of amniotic fluid surrounding the fetus.
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fetus prior to birth. 77 Physicians can perform an amniocentesis during the
78
second trimester between fifteen and twenty-four weeks gestation.
Both forms of IPD, amniocentesis and CVS, cost around $1,500, are
uncomfortable for the woman, and have about a 0.5 to 1 percent risk of
miscarriage. 79 As a result, most women currently do not opt for any form of
diagnostic prenatal genetic testing unless a serious genetic or chromosomal
disorder runs in their family or they screen high risk for a disease that would
cause them to consider pregnancy termination.80 In addition, these risks limit
the conditions for which physicians will offer IPD, as ethically they must
balance the risks of a procedure with its benefits. 81 Therefore with IPD, a
physician should only offer testing when the informational benefit provided
to the couple could outweigh the miscarriage risk and discomfort. 82 This
limits both the number of women who undergo prenatal diagnostic testing
and the conditions for which testing is available.
2. Preimplantation Genetic Diagnosis
Women can also receive reproductive genetic testing prior to pregnancy
in the context of in vitro fertilization (IVF) accompanied by preimplantation
77. Id. at 4-7.
78. Id. at 7.
79. Wright, supra note 7, at 11. The risk of miscarriage associated with CVS and
amniocentesis varies by the skill of the provider, and can in some cases be much lower (I in
200). See A.B. Caughey, L.M. Hopkins &, M.E. Norton, Chorionic Villus Sampling
Compared with Amniocentesis and the Difference in the Rate of Pregnancy Loss, 108
OBSTETRICS & GYNECOLOGY 612, 612-16 (2006) (performed over 20 years at UCSF and
finding an overall miscarriage rate of 3.2% for CVS and .8% miscarriage rate for
amniocentesis); A. Tabor, C.H.F. Vestergaard, & 0. Lidegaard, Fetal Loss Rate After
Chorionic Villus Sampling and Amniocentesis: an 11-Year National Registry Study, 34
ULTRASOUND OBSTETRICS & GYNECOLOGY 19, 19-24 (2009) (performed in Denmark, but
demonstrating miscarriage rates of 1.4% for amniocentesis and 1.9% for CVS, and showing a
significant reduction in miscarriage in clinics that performed more than 1500 CVS procedures
a year). The price for amniocentesis and CVS vary by hospital and provider, however general
estimates range from $110042000. See e.g. KayCircle, What is the Average Cost of
Amniocentesis? available at: http://www.kaycircle.com/What-is-the-average-cost-of-an-
Amniocentesis-without-health-insurance-Amniotic-fluid-test-AFT-Price-Range.
80. See Anita de Jong et al., Non-invasive Prenatal Testing: Ethical Issues Explored,
18 EUR. J. HUM. GENETICS 272,273 (2010).
81. Greely, supra note 70, at 289; Dagmar Schmitz et al., No Risk, No Objections?
Ethical Pitfalls of Cell-free Fetal DNA and RNA Testing, 339 BRIT. MED. J. 165, 165 (2009).
82. While the informational value to the couple is not for the physician to decide in a
particular case, the physician should not offer testing for those conditions where the benefit
could not outweigh the clinical risk.
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genetic diagnosis (PGD). 83 PGD permits prospective parents to make
reproductive decisions prior to implantation of an embryo, which enables
them to avoid a termination decision based on the genetic and chromosomal
status of their fetus. 84 To perform IVF, a clinician harvests eggs from the
woman and combines each egg with sperm in a Petri dish in hopes of
fertilization.85 On the third day after fertilization, an embryologist removes
one cell from each embryo that has fertilized and developed to an eight-cell
stage, and then sends the DNA inside that cell to a laboratory for genetic
testing.8 6 The prospective parents can then decide which embryos to transfer
to the womb based on the results of the test.
87
PGD has a number of drawbacks that limit its use in the United States to
a few thousand cycles per year. 88 First and foremost, this method of
reproductive genetic testing is significantly more expensive than prenatal
testing, costing around $10,000 to $12,000 per IVF cycle and an additional
$6,500 to $8,500 for PGD.8 9 The sheer cost alone is sufficient to make PGD
financially inaccessible for many couples. Second, the procedure carries risks
to both the woman undergoing the procedure and the fetus. 90 In order to
retrieve the eggs for fertilization, the woman must take large doses of
hormones to trigger her ovaries to release more than one egg, be put under
anesthesia, and have minor surgery. 91 Children born through IVF also
experience slightly higher rates of congenital malformations and birth
defects.92 Finally, in addition to the expense and the risk, each IVF and PGD
83. Preimplantation Genetic Diagnosis (PGD), IVF-INFERTILITY.COM (June 19, 2011),
http://www.ivf-infertility.com/ivf/pgd.php.
84. Id.
85. Id.
86. Id.
87. Id.
88. Jaime S. King, Predicting Probability: Regulating the Future of Preimplantation
Genetic Screening, 8 YALE J. HEALTH POL'Y L. & ETHICS 283,291 n.28 (2008). The number of
PGD cycles that occur each year is difficult to calculate as this data is not collected by any
entity, including the CDC as part of its ART database. The most recent data from 57 clinics in
Europe found that 5887 cycles were completed in 2007, resulting in 1206 babies born. J.C.
Harper et al., ESHERE PGD Consortium Data Collection X. Cycles from January to
December 2007, with Pregnancy Follow-up to October 2008, 25 HUM. REPRODUCTION 2685,
2685 (2010).
89. See, e.g., In Vitro Fertilization, NOVAIVF.COM, http://novaivf.com/cost-ivf-pgd.htm
(last visited Aug. 3,2011).
90. King, supra note 88, at 303-08.
91. Id. at 308.
92. Id. at 303-08.
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cycle only has about a 30 percent chance of producing a viable pregnancy,
which may cause many prospective parents to opt against the procedure.
93
3. NIPD through CffDNA Testing
While prenatal and preimplantation diagnostic testing can provide
parents with the ability to engage in reproductive selection for a wide variety
of conditions, due to the risks and expense of the procedures, prospective
parents use these methods only in rare instances. 94 By comparison, cffDNA
testing has three critical features that differentiate it from current methods of
reproductive genetic testing in ways that will remove many of the existing
roadblocks for prenatal genetic testing. It offers diagnostic information from
a non-invasive test that is available early in pregnancy, and will be
comparatively less expensive.
First, the cffDNA testing can be completed from a maternal blood test,
making it non-invasive of the uterus.95 Therefore, it eliminates any risk to the
fetus and reduces discomfort to the mother, which may significantly alter
pregnant women's opinions regarding testing.96 Currently, less than 2 percent
of all pregnant women receive diagnostic prenatal or preimplantation genetic
testing due to the expense, discomfort, and risks to mother and fetus.
97
However, in California, where all pregnant women are required by law to be
offered prenatal screening, which offers only probabilistic information,
approximately 70 percent accept. 98 This demonstrates that a substantial
majority of pregnant women may have both an interest in genetic
information about their fetus and a willingness to undergo a blood test to
gain that information. A woman who was willing to have a blood test to
obtain probabilistic genetic risk information is likely to be equally willing to
93. CENTERS FOR DISEASE CONTROL AND PREVENTION, AMERICAN SOCIETY FOR
REPRODUCTIVE MEDICINE, & SOCIETY FOR ASSISTED REPRODUCTIVE TECHNOLOGY, 2008
ASSISTED REPRODUCTIVE TECHNOLOGY SUCCESS RATES: NATIONAL SUMMARY AND FERTILITY
CLINIC REPORTS 22 (U.S. Department of Health and Human Services 2010), available at
http://www.cdc.gov/art/ART2008/PDF/ART 2008_Full.pdf (last visited Aug. 3, 2011).
94. Peter Benn & Audrey Chapman, Practical and Ethical Considerations of
Noninvasive Prenatal Diagnosis, 301 JAMA 2154, 2154 (2009).
95. Id. While NIPD is generally referred to as being non-invasive, it does require a
needle stick for the blood draw.
96. Benn & Chapman, supra note 94, at 2155.
97. See Greely, supra note 70, at 289.
98. Jelliffe-Pawlowski et al., supra note 72, at 2456. California offers prenatal genetic
screening to all pregnant women. As a result, the uptake of prenatal screening is likely to be
higher than the rest of the country. However, this finding does suggest a desire among women
to have such information. See id
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have a similar blood test that would provide her with significantly more
accurate or diagnostic information.
99
At initial obstetrics appointments, most pregnant women already
undergo a number of blood tests, which should ease the integration of NIPD
into early prenatal care for both physicians and patients. 1 Physicians would
need to add an additional lab test to their standard list, and patients must be
willing to have an additional vial of blood drawn. As a result of the ease of
integrating the testing procedure, pregnant women are more likely to have
the test and view it as part of standard prenatal care. One expectant mother
stated upon being told about NIPD, "If I had the opportunity to take a blood
test instead of amniocentesis, I would take the blood test hands down ...
You get poked a million times anyway when you are pregnant. Another
blood test is no big deal. But a needle going in the amniotic sac and
potentially harming the baby is scary, particularly at an older age." l  As a
result, more women may decide to have the test, and more physicians may
offer it for a wider range of conditions.
Second, NIPD can be given to women very early in the pregnancy, in
some cases as early as seven to nine weeks gestation. 10 2 This offers
99. In fact, women may be more willing to have a non-invasive diagnostic test than a
non-invasive screening test, due to the need to verify a positive screening test with an invasive
procedure, such as an amniocentesis or CVS. Initially, many obstetricians may advise patients
to follow any NIPD testing results with IPD to verify results. However, if NIPD methods
prove as accurate as the early clinical trials suggest, it seems likely that it will replace IPD
altogether. See Loes Kooij et al., The Attitude of Women Toward Current and Future
Possibilities of Diagnostic Testing in Maternal Blood Using Fetal DNA, 29 PRENATAL
DIAGNOSIS 164, 166 (2009) (81 percent of pregnant women felt that NIPD should be offered
to all pregnant women to diagnose Down syndrome, while only 74 percent felt that all
pregnant women should be offered prenatal genetic screening for Down syndrome).
100. See Routine Tests in Pregnancy, AM. COLLEGE OF OBSTETRICIANS AND
GYNECOLOGISTS, http://www.acog.org/publications/patient education/bp133.cfm (last visited
Feb. 21, 2011); William Sears & Martha Sears, Prenatal Checkups: Month by Month What to
Expect When Seeing Your Doctor, ASKDRSEARs.COM, http://www.askdrsears.com
/html/l/t011200.asp (last visited Feb. 21, 2011), Mayo Clinic Staff, Prenatal Care First
Trimester Visits, MAYOCLINIC.COM, http://www.mayoclinic.com/health/prenatal-care
/PR0008 (last visited Feb. 1,2011).
101. New Down syndrome Test Could Cut Healthy Baby Deaths, Non-Invasive Blood
Test Could Eliminate Miscarriage Risk of Amniocentesis, ABCNEWS.GO.COM,
http://abcnews.go.com/Health/prenatal-test-down-syndrome-cut-baby-deaths-
amniocentesis/story?id=12594077&page=2 (last visited Feb. 21, 2011).
102. Alison Hall et al., Non-Invasive Prenatal Diagnosis Using Cell-Free Fetal DNA
Technology: Applications and Implications, 13 PUB. HEALTH GENOMICS 246, 248 (2010).
Seven weeks gestation means seven weeks from the first day of the woman's last menstrual
period. By this measure, a woman would miss her period at four to five weeks gestation.
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significant benefits for decision-making and clinical care. In comparison, the
earliest CVS and amniocentesis can be offered is ten and fifteen weeks,
respectively.103 However, most women will not receive diagnostic
information until later in their second trimester, because most of them only
opt for amniocentesis following a positive prenatal screening result.'0 4 As
noted above, prenatal screening protocols cannot be completed prior to
fifteen weeks, and then a pregnant woman must wait for the results. If her
pregnancy screens "high risk," and she wants to consider IPD, then she must
make an appointment with her obstetrician and/or genetic counselor to
determine whether to undergo an amniocentesis. If she opts to have the IPD,
she must schedule an appointment, have the procedure and again await the
results. All of this can take a few weeks, meaning that if her fetus tests
positive for a disorder, she will likely decide whether to terminate the
pregnancy closer to eighteen to twenty weeks. Many states prohibit
pregnancy terminations beyond twenty-four weeks gestation except to save
the life of the mother, which greatly limits the amount of time prospective
parents have to think about their decision and the options available with
respect to termination. 05
In addition, possessing diagnostic information early in the first trimester
provides significant clinical benefits. In some cases, early detection can
improve clinical decision-making by permitting prenatal treatment to
alleviate symptoms of a disorder or improve the clinical management of the
pregnancy or birth. 10 6 For instance, administering antenatal dexamethasone to
female fetuses affected by congenital adrenal hyperplasia at or before ten
weeks gestation can reduce genital ambiguity. 10 7 Also, as noted above,
testing levels of cffDNA in maternal blood can identify abnormal placental
function before significant symptoms arise allowing for improved
American Pregnancy Association, Calculating Your Dates: Gestation, Conception and Due
Date, available at http://www.americanpregnancy.org/duringpregnancy/calculatingdates.html.
Currently, aneuploidy testing is offered at nine weeks, but given the presence of cffDNA in
maternal blood earlier in the pregnancy, companies are likely to move this date forward.
103. THE CALIFORNIA PRENATAL SCREENING PROGRAM, supra note 71.
104. See Naomi Nakata, Yuemei Wang & Sucheta Bhatt, Trends in Prenatal
Screening and Diagnostic Testing Among Women Referred for Advanced Maternal Age, 30
Prenatal Diagnosis 198, 198-206 (2010).
105. See AUBREY MILUNSKY & JEFF MILUNSKY, GENETIC DISORDERS AND THE FETUS:
DIAGNOSIS, PREVENTION AND TREATMENT 940 (6th ed. 2010).
106. See Hall et al., supra note 102, at 248-49.
107. Id; see generally Robert J. P. Rijnders et al. Clinical Applications of Cell-free
Fetal DNA from Maternal Plasma, 103 OBSTETRICS & GYNECOLOGY 157, 157-64 (2004).
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monitoring and prenatal care from an earlier point in the pregnancy. 1° The
earlier timing of NIPD offers significant benefits both clinically and for
patients' decision-making processes. The significance of this timing shift
will be further discussed in more detail in Part IIIC.
Third, NIPD will be less expensive than current forms of prenatal or
preimplantation genetic testing, making it more easily accessible. The cost of
DNA sequencing is rapidly dropping. 1°9 In 2008, Steve Quake estimated the
cost of his aneuploidy test would be approximately $700." ° By 2010, the
price had dropped nearly 60 percent to $300.111 As DNA sequencing
technology improves, the cost of genetic testing is expected to continue to
drop, so much so that the cost of sequencing of an entire human genome has
been estimated to be under $1,000 within two years. 12 While the reduction
in cost will lower the expense of all prenatal and preimplantation genetic
testing, the costs of IPD and PGD will remain much higher due to the clinical
expertise and setting required to perform the procedure. As a result, NIPD
will offer newly pregnant women a less risky, comparably inexpensive way
to find out a great deal about their fetus' genetic makeup almost immediately
upon discovering they are pregnant.
II. THE DIFFERENCE cffDNA MAKES
This combination of factors raises the importance of considering the
implications of widespread reproductive genetic testing from an interesting
thought exercise to an imperative social concern. It does so by increasing the
number of women who will undergo reproductive genetic testing, broadening
the scope of conditions and characteristics that can be tested for, and
providing genetic information to parents at a point in the pregnancy when the
information is more actionable.
108. See Wright & Burton, supra note 4, at 145; Hahn, et al, supra note 23.
109. Colin Hill, Beyond the $1000 Genome, FORBES, available at
http://www.forbes.com/sites/colinhill/2012/02/09/beyond-the-1 000-genome/.
110. Steven R. Quake, Lecture, Implications of Maternal Serum Fetal Cell Free DNA
Conference, STANFORD LAW SCHOOL (May 7, 2010), http://www.law.standford.edu/display
/images/dynamic/events media/20100507_CLBMatemalSerum-001 .mov.
111. Id.
112. Rachel Lehmann-Haupt, Pacific BioScience Has a $1000 Genome Test That
Could Save Your Life - And The Industry, BNET HEALTHCARE (March 4, 2010),
http://www.bnet.com/blog/healthcare/pacific-bioscience-has-a- I 000-genome-test-that-could-
save-your-life-and-the-industry/1824. While this timeline may be ambitious, it nonetheless
demonstrates the rapid decrease in high throughout genetic screening.
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A. Increase in Volume
Due to the clinical advantages of NIPD over existing reproductive
genetic testing techniques, its adoption into clinical practice will expand the
number of pregnant women who receive prenatal genetic testing. The scope
of the increase will depend on three major factors: 1) the underlying patient
demand for fetal genetic information; 2) the rate of adoption of NIPD testing
by OB/Gyns; and 3) the level of insurance coverage for the procedure.
Importantly, these three factors are not independent of one another, such that
as patient demand and physician support increases, so will the likelihood of
insurance coverage. The inverse is also true, as insurance coverage expands
patient demand and physician adoption will also increase.
Patient demand for fetal genetic information depends on the ease of
obtaining the information and its quality. Pregnant women will be more
likely to undergo reproductive genetic testing as expense, discomfort and risk
decrease and the quantity and quality of genetic information available
increase." 3 NIPD offers an improvement over current reproductive genetic
testing technologies at each of these levels. As mentioned above, the
reduction in risk and discomfort associated with NIPD will likely cause
many women to recalculate their decision to have prenatal screening and
testing. One group of pregnant women, surveyed in the Netherlands, strongly
supported the use of NIPD on a societal level for health-related conditions." 14
The study found that 81 percent of pregnant women agreed that NIPD should
be offered to all pregnant women to diagnose Down syndrome, while only 45
percent agreed that invasive diagnostic tests should be offered to all woman
to diagnose Down syndrome. 1 5 While the attitudes of pregnant women in the
U.S. may differ somewhat from pregnant women in the Netherlands, the
demand for fetal genetic information obtained in a non-invasive manner is
likely to be quite high." 6 Further, as with all genetic testing, the cost of
NIPD should continue to decrease, while the range of conditions available
for testing and the reliability of information should increase." 17
113. Benn & Chapman, supra note 94, at 2154.
114. Kooij, supra note 99, at 166.
115. Id. Interestingly, a comparison group of female medical students felt strongly that
NIPD is "an important asset in screening for Down syndrome" (89 percent), but only about
half felt that it should be offered to all pregnant women to test for Down syndrome (49
percent). Id.
116. Benn & Chapman, supra note 94, at 2154.
117. Greely, supra note 70, at 290.
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Similarly to patients, physicians will adopt a new technology when the
balance of its advantages and disadvantages offer an improvement over a
similar comparison for the existing technology." 8 For instance, if a new
medical device offers greater clinical advantages with fewer disadvantages
for a similar price, the device will likely be widely adopted. With NIPD, the
clinical advantages of diagnostic genetic information at an earlier point in the
pregnancy accompanied by an substantial decrease in risk and cost when
compared to current prenatal and preimplantation genetic diagnosis make the
case for its adoption quite compelling."
9
The potential for a wrongful birth lawsuit may also speed the integration
of NIPD into standard prenatal care. Wrongful birth suits permit prospective
parents to sue a physician for negligence in testing or failing to offer genetic
tests, that if given, would have identified a genetic disorder in the fetus and
permitted the prospective parents to abort the fetus.120 Wrongful birth suits
do not permit the prospective parents to recover for the genetic disorder
itself, but rather for the loss of the choice to terminate the pregnancy and the
damages that result from that loss. 12 1 Physicians have argued in wrongful
birth lawsuits that the risk of miscarriage associated with IPD justified not
offering diagnostic testing to the patient. Given the reduced risk of fetal
miscarriage associated with NIPD, physicians may feel obligated to offer
prospective parents NIPD for a wide range of genetic disorders and
conditions not currently part of the prenatal screening protocol to avoid a
potential suit for wrongful birth.
As mentioned above, the speed of NIPD adoption will also largely
depend on whether insurance companies cover its use. Insurance coverage
will increase patient demand for the test and ease physician adoption. In the
United States, both private and public health insurance offer coverage for
prenatal care. 22 Private health plans are becoming more reluctant to offer
coverage for new technologies in the absence of clinical research
118. Josd J. Escarce, Externalities in Hospitals and Physician Adoption of a New
Surgical Technology: An Exploratory Analysis, 15 J. HEALTH ECON. 715, 719 (1996).
119. Hall et al., supra note 102, at 248-49; see also Mary Norton, Professor of
Obstetrics & Gynecology, Stanford Medical School, Free Fetal DNA: The Provider and
Patient Prospective, Lecture at the Stanford University Implications of Maternal Serum Fetal
Cell Free DNA Conference (May 7, 2010).
120. See e.g., Lininger v. Eisenbaum, 764 P.2d 1202, 1212 (Colo. 1988); Berman v.
Allan, 404 A.2d 8, 15 (Pa. 1979); Becker v. Schwartz, 386 N.E.2d 807, 819 (N.Y. 1978).
121. DAN B. DOBBS, THE LAW OF TORTS §291, at 793 (West 2000).
122. KAISER FAMILY FOUNDATION, STATE MEDICAID COVERAGE OF PERINATAL
SERVICES: SUMMARY OF STATE FINDINGS NOVEMBER 2009 10 (2009), available at
www.kff.org/womenshealth/upload/8014.pdf.
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demonstrating its effectiveness overall, and its cost-effectiveness over
existing technologies. 123 Private insurance companies are unlikely to cover
NIPD without a rigorous testing period, but given NIPD's advantages over
existing prenatal testing, eventual coverage of NIPD testing seems likely.
This is especially true as each additional genetic disorder detected presents
the possibility that the parents will abort the fetus, which, if born, could
prove very costly for the insurance company. 24
Given this potential insurance company viewpoint, it is essential to
ensure that NIPD is presented in a way that enhances the ability of pregnant
women to make an informed decision based on sound information and a
clear assessment of her personal values, rather than simply promoting testing
and abortion. Unfortunately, private insurance companies often reimburse for
diagnostic tests at significantly higher levels than for pretest counseling. 125
Such a reimbursement model might lead physicians to spend their very small
amount of compensated time encouraging NIPD, rather than helping patients
determine which NIPD tests, if any, they desired. 126 If patients believe that
NIPD testing for a wide range of conditions is an expected and accepted part
of "good prenatal care", rather than an option to receive information that may
assist in their reproductive decisions, many women may receive unexpected
and unwanted information.'27 Such a result could be extremely detrimental
for pregnant women seeking NIPD and should be avoided.
Obtaining public health insurance coverage through Medicaid will
present additional challenges.128 In the last two decades, Medicaid has
123. Wade Aubrey, Professor of Medicine at UC San Francisco, Lecture at the
Stanford University Implications of Maternal Serum Fetal Cell Free DNA Conference (May 7,
2010).
124. Carolyn Jacobs Chachkin, What Potent Blood: Non-Invasive Prenatal Genetic
Diagnosis and the Transformation of Modern Prenatal Care, 33 AM. J. L. MED. 9, 40-43
(2007) (providing a detailed cost analysis of the financial benefits of covering NIPD for
insurance companies); see also LORI HAMMON, THE COUNCIL FOR RESPONSIBLE GENETICS,
NON-INVASIVE PRENATAL DIAGNOSIS 24 (2011).
125. Sonia Mateau Suter, The Routinization of Prenatal Testing, 28 AM. J. L. & MED.
233,246 (2002).
126. Id.
127. The idea that unwanted and unexpected genetic information can be toxic for
pregnant women is discussed further in Part IIIB.
128. THE KAISER COMMISSION ON MEDICAID AND THE UNINSURED & GEORGETOWN
UNIVERSITY HEALTH POLICY INSTITUTE CENTER FOR CHILDREN AND THE FAMILY, NEW
FEDERAL FUNDING AVAILABLE TO COVER IMMIGRANT CHILDREN AND PREGNANT WOMEN (July
2009), available at http://www.kff.org/medicaid/7915.cfm. The Children's Health Insurance
Plan (CHIP) also can be used to cover prenatal care for pregnant women through the "unborn
child" option, which provides for care to the fetus via the pregnant woman. Id. Overall this
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become the single largest payer of maternity related services in the United
States, financing four in ten of all births annually. 129 Medicaid currently
covers the poor, aged, disabled, blind, and their dependent children; states
can also extend coverage to low-income pregnant women and children.' 30 In
keeping with the recommendations of the American College of Obstetrics
and Gynecology (ACOG) that all pregnant women should be offered prenatal
genetic screening and/or diagnosis, in a survey of forty-four Medicaid
programs, thirty-six states and the District of Columbia (D.C.) reported
currently covering prenatal genetic screening services.' 31 In addition, of the
forty-four Medicaid programs, forty states and D.C. cover prenatal genetic
diagnosis through CVS and forty-two states and D.C. cover it through
amniocentesis.' 32 Twenty-three state Medicaid programs and the D.C.
Medicaid program also cover genetic counseling services for pregnant
women. 133 In those states that have already adopted prenatal genetic
screening, testing and counseling, coverage of a less expensive, non-invasive
genetic testing option should be perfunctory, provided the accuracy and
reliability of the test were similar.'
34
For those state Medicaid programs and private insurance plans that do
not currently cover prenatal genetic testing and screening, the benefits of
NIPD may shift the balance in favor of coverage. Since the children
subsequently born will be covered either by the Medicaid or the parents'
private insurance plan, engaging in early diagnosis through NIPD and
prenatal treatment for placental complications, RhD typing and CAH may
prove cost effective in comparison to later prenatal or postnatal treatment.
When prenatal diagnosis is used to inform a termination decision, earlier
does not cover a great majority of prenatal care. Id. The Children's Health Insurance Plan
Reauthorization Act (CHIPRA) also now permits states to use CHIP federal matching funds to
cover pregnant women who are above the income eligible for Medicaid coverage or above
185 percent of the federal poverty level, whichever is higher. Id.
129. KAISER FAMILY FOUNDATION, supra note 122, at 10. Medicaid coverage of births
ranges state to state from 23 percent of births in New Hampshire to 63 percent of births in
Louisiana. Id.
130. BARRY FURROW ET AL., HEALTH LAW 822-23 (6th ed. 2008).
131. KAISER FAMILY FOUNDATION, supra note 122, at 15.
132. Id. ACOG recommends that physicians offer all pregnant women, regardless of
age, screening tests for Down syndrome and certain chromosomal abnormalities. ACOG also
recommends that all pregnant women have the option of having a diagnostic test rather than a
screening test for genetic and chromosomal abnormalities. ACOG Committee on Practice
Bulletins-Obstetrics et al., ACOG Practice Bulletin No. 77: Screening for Fetal
Chromosomal Abnormalities, 109 OBSTETRICS& GYNECOLOGY 217, 217-27 (2007).
133. KAISER FAMILY FOUNDATION, supra note 122, at 18.
134. Smith et al., supra note 27, at 632; Chachkin, supra note 124, at 43.
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diagnosis can reduce the rate and severity of complications during an
abortion, as the earlier a termination occurs, the lower the risk of
complications. 135 If women decide to terminate prior to nine weeks gestation,
they may elect to have a "medical" rather than surgical abortion, which also
has lower complication risks. 136 Many private insurance plans cover both
surgical and medical abortions, as well as any treatments that arise from
complications during the procedure.' 37 In the case of Medicaid, the Hyde
Amendment prohibits the use of federal funds for abortion' 38 except in the
case of rape, incest, or when the mother's life is in danger,' 39 but states may
elect to use their own funds to offer additional benefits. Thirty-two states do
not offer funding for abortion beyond the federal level, but three of those
have explicitly created an exception that permits the use of state funds for an
abortion in the case of fetal abnormality. 14° Likewise, seventeen states and
D.C. have gone beyond the federal minimum coverage guidelines and offer
funding for all or most medically necessary abortions, medical or surgical. 141
Fewer complications and a reduction in surgical abortions can provide cost
savings over current methods of prenatal diagnosis followed by pregnancy
termination. For the reasons stated above, the state Medicaid programs and
private insurance plans that do not currently cover prenatal genetic diagnosis
may be more likely to do so once NIPD becomes commercially available. 1
42
On the other hand, citizens in some states may voice significant moral
opposition to Medicaid coverage of NIPD due to the perception that its use
will increase abortion. 143 As a result, some state Medicaid programs may
refuse to offer NIPD or will limit its use to a smaller set of conditions for
political reasons related to protecting unborn life and narrowing the reasons
for which a woman could seek an abortion. Bans on Medicaid coverage of
135. Hall et al., supra note 102, at 249.
136. Id.
137. See Danco Laboratories, Insurance and Medicaid, EARLYOPTIONPILL.COM,
http://www.earlyoptionpill.com/section/healthprofessionals/insurance-and-medicaid (last
visited Dec. 1, 2010) (listing the coverage practices major insurers in sixteen states).
138. 42 C.F.R. § 441.200 (2010).
139. 42 U.S.C. § 1397ee(c)(1) (2006).
140. State Policies in Brief: State Funding ofAbortion Under Medicaid, GUTTMACHER
INSTITUTE (Feb. 1, 2011), http://www.guttmacher.org/statecenter/spibs/spib SFAMpdf
141. Id.; Danco Laboratories, supra note 137 (stating Arkansas, Arizona, California,
Connecticut, Illinois, Maryland, Massachusetts, Minnesota, Montana, New Jersey, New
Mexico, New York, Oregon, Vermont, Washington, and West Virginia all offer some amount
of coverage for medical abortions).
142. However, some states may limit the use of NIPD entirely or for certain conditions
in order to limit the number of abortions that follow NIPD.
143. Chachkin, supra note 124, at 44.
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NIPD in some states could significantly limit access to NIPD Medicaid
recipients, further increasing health disparities between socioeconomic
groups in ways that could have significant societal repercussions. If genetic
diseases became largely associated with lower socioeconomic groups,
discrimination against those with diagnosable genetic disorders could
increase and the amount of societal resources for individuals living in society
with those disorders could decline. As a society, we should strive to ensure
that NIPD is offered on an equal basis to all pregnant women.144
Overall, however, NIPD offers many benefits over current prenatal and
preimplantation genetic screening and diagnosis options to pregnant women,
physicians, and insurance providers. These benefits will make physicians
more likely to recommend NIPD, patients more likely to accept it, and public
and private insurance providers more likely to cover it. Each of these factors
will contribute to a substantial increase in the number of pregnant woman
undergoing prenatal genetic testing. 145
B. More Information
In addition to the increase in women that will obtain diagnostic genetic
testing, NIPD will significantly broaden the number of conditions for which
prenatal diagnosis is both available and clinically appropriate. 146 The scope
of current reproductive genetic testing is limited by both risk and expense.
Prenatal genetic screening only provides relative risk information on a few
serious conditions for which non-genetic biological markers exist, which
greatly limits the number of conditions available for screening. Current
prenatal screening programs include screening for neural tube defects,
abdominal wall defects, SLOS, Down syndrome and Trisomy 18.147
Physicians generally only offer IPD if a woman has a family history of a
genetic or chromosomal disorder, screens high risk for a specific condition,
or is high risk due to age or other medical condition.1 48 The risks of IPD limit
144. See Radhika Rao, Equal Liberty: Assisted reproductive Technology and
Reproductive Equality, 76 GEO. WASH. L. REV. 1457, 1457-58 (2008) (for a thorough
discussion of the importance of equality in reproductive rights).
145. See de Jong et al., supra note 80, at 273.
146. Id. at 272; Smith et al., supra note 27, at 633.
147. The California Prenatal Screening Program screens for neural tube defects,
abdominal wall defects, Down syndrome, Trisomy 18, and SLOS, other programs may screen
for fewer conditions. THE CALIFORNIA PRENATAL SCREENING PROGRAM, supra note 71.
148. Amniocentesis-Series, MEDLINE PLUS, http://www.nlm.nih.gov/medlineplus/ency
/presentations/100192 1 .htm (last updated Sept. 2, 2009). But see, ACOG Committee on
Practice Bulletins-Obstetrics et al., supra note 132, at 217-27 (recommending that
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the appropriateness of performing the tests for less severe medical
conditions, sex, behavioral and cosmetic traits in isolation, as medical ethics
requires that the benefit of the information outweigh the risks of the
procedure needed to obtain that information. In addition, few women would
be willing to undergo the discomfort and expense of IVF and PGD without
being high risk for a certain disease or condition.
149
As a relatively inexpensive, non-invasive blood test, NIPD does not
share these limitations. First, the benefit of nearly any kind of information
would appear to outweigh the risks associated with performing the test.'
50
Second, a number of start up companies already offer NIPD testing directly
to consumers via the internet for a range of conditions, including RhD status
and fetal sex. 151 These kinds of companies will likely offer testing for any
condition for which there is consumer demand. Third, the availability of
whole genome analysis from cffDNA from maternal blood serum will permit
DTC companies and physicians to test fetuses for potentially hundreds of
genetic diseases and all chromosomal abnormalities, as well as
predispositions to other multifactorial conditions at the same time. 52 The
ability to conduct a whole genome analysis of a fetus from a maternal blood
physicians offer IPD to all pregnant women). However, at least one study suggests that
ACOG's recommendation did not affect physician practice. Julie Reichling et al., Abstract,
Amniocentesis for Maternal Concern: The Impact of A COG Guidelines, 2010 ACMG ANNUAL
CLINICAL GENETICS MEETING, available at http://acmg.omnibooksonline.com/2O l0/data
Ipapers/l 99.pdf(last visited Feb. 19, 2010).
149. Common non-medical PGD uses include non-medical sex selection and HLA
typing to ensure that the future child could be a blood and tissue donor for an existing sick
child. Susannah Baruch et al., Genetic Testing of Embryos: Practices and Perspectives of U.S.
In Vitro Fertilization Clinics, 89 FERTILITY & STERILITY 1053, 1055 (2008), available at
http://www.dnapolicy.org/resources/GeneticTestingofEmbryos.pdf (showing that only I
percent of PGD cycles-43 overall-in 2005 were initiated for HLA typing and 9 percent-
320 overall-were initiated for non-medical sex selection).
150. See Smith et al., supra note 27, at 633.
151. See Non-invasive Prenatal DNA Testing, PRENATAL GENETICS CENTER,
http://www.prenatalgeneticscenter.com/gender-intro.asp (offering sex determination at 10
weeks); RhD Genotyping, LENETIX MEDICAL SCREENING LABORATORIES, INC.,
http://www.lenetix.com/html/rhd srygenotyping.html (offering RhD status at 15 weeks);
Prenatal Testing, DNAPLUS, hup://www.dnaplus.com/prenataltests.htm (follow "Fetal Cell
Prenatal Paternity Test" and "Fetal Cell Prenatal Gender Test" hyperlinks) (offering paternity
testing at 13 weeks and sex determination 10 weeks); FAQs About the DNA Gender Test,
CONSUMER GENETICS, INC., http://www.consumergenetics.com/gender-test/boy-or-girl-
faqs.php (offering sex determination at 10 weeks); Sending Samples to JBGRL, THE BRISTOL
INSTITUTE FOR TRANSFUSION SCIENCES, http://ibgrl.blood.co.uk/ReferenceServices
/RefSerSendSamples.htm (offering RhD status at 16 weeks and sex determination at 7 weeks).
152. Lo et al., supra note 3, at 1.
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sample means that the scope of genetic information available through NIPD
will be limited only by our knowledge and understanding of genetics. The
combination of genome-wide analysis and minimal risks associated with
NIPD will mean that for nearly all genetic conditions a fetus' status will be
both available and clinically appropriate to test for.
Some scholars have argued that this "specification creep '' 153 may occur
regardless of a shift from IPD to NIPD. In fact, because testing for multiple
conditions at once would be possible through both technologies, one could
argue that the invasiveness of the procedure would provide an incentive for
parents to test for as many abnormalities or genetic conditions of interest as
possible to justify the risk of testing and potentially termination. 54 For
several years now, geneticists have been discussing the merits of broadening
the scope of prenatal diagnostic testing, as genetic testing capabilities have
155 1 56improved. 55 Neither NIPD nor IPD requires a specific breadth of testing.
The scope can be determined on a patient-by-patient basis, set by practice
guidelines for the profession, or established by policymakers. 157 However,
regardless of a whether clinicians offer a wide range of tests through IPD as
well, an NIPD protocol will increase the number of women receiving testing
for an expanded set of conditions. And as noted above, the societal impact of
NIPD will depend on the combination of volume of women undergoing
testing, the conditions for which they test, and how they use the information.
C. More Actionable
How prospective parents use cffDNA test results will be a function of
how "actionable" the information is, i.e., how it changes the options open to
parents. Because NIPD is available so early in the pregnancy, its test results
are more actionable than IPD results, as they offer more options for
information gathering and treatment, as well as termination. 5 8 First, NIPD
offers prospective parents more time to learn about the condition their fetus
153. Wright, supra note 7, at 29; Hall et al., supra note 102, at 250.
154. See de Jong et al., supra note 80, at 274.
155. See id.; Caroline Ogilvie et al., Current Controversies in Prenatal Diagnosis 3:
For Prenatal Diagnosis, Should We Offer Less or More Than Metaphase Karyotyping?, 29
PRENATAL DIAGNOSIS 11, 13 (2009); Evelyne Shuster, Microarray Genetic Screening: A
Prenatal Roadblock for Life?, 369 LANCET 526, 528 (2007).
156. de Jong et al., supra note 80, at 274.
157. Reaching consensus on which conditions are appropriate for prenatal testing has
been shown to be next to impossible and the regulatory challenges of doing so will be more
fully discussed in Part IV.
158. Benn & Chapman, supra note 94, at 2155-56.
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has, what support structures exist in society for individuals with that
condition, and what life with an affected child would entail. In 2008,
Congress passed the Prenatally and Postnatally Diagnosed Conditions
Awareness Act, which aims to help women who receive a diagnosis of Down
syndrome or other condition with "up-to-date information on the range of
outcomes for individuals living with the diagnosed condition, including
physical, developmental, educational, and psychosocial outcomes.' 59
Physicians could further supplement these requirements by providing
pregnant women with information and resources to help them understand the
realities of life for families living with disability. NIPD offers pregnant
women significantly more time than current IPD protocols to make use of
such resources and potentially connect with families of children with a
similar diagnosis.'
60
Secondly, for women who would consider termination, more may choose
to undergo NIPD because it offers diagnostic information at a point in the
pregnancy when the termination options may be more tolerable both
physically and emotionally. 161 Until nine weeks after the first day of her last
menstrual period, a woman can have a medical abortion, as opposed to a
surgical abortion.162 In a medical abortion, the woman takes a combination of
medications, usually misoprostal and mifepristone, to end the pregnancy and
cause the uterine lining to shed.163 Medical abortions are non-invasive and do
not require anesthesia, and therefore a woman can take the medication and
abort the fetus in her own home rather than in a clinical setting. 164 Even if a
woman does not decide to terminate during the window when a medical
abortion is possible, surgical abortions performed earlier in the pregnancy are
less complicated and safer.' 65 In contrast, surgical abortions performed after
amniocentesis occur in the second trimester and require much more invasive
procedures.166 Dilation and Evacuation (D&E), the most common procedure
159. PRENATAL TESTING AND DISABILITY RIGHTS 8 (Erik Parens & Adrienne Asch eds.,
2000).
160. Benn & Chapman, supra note 94, at 2155-56.
161. In this section, I do not mean to suggest that women should find abortion more
tolerable emotionally or physically, just that some women may find it more tolerable at an
earlier time.
162. Patient Education: Medical Versus Surgical Abortion, UCSF MEDICAL CENTER,
http://www.ucsfliealth.org/adult/edu/abortion.html.
163. Id.
164. Id.
165. Hall et al, supra note 102, at 249.
166. Surgical Abortion Procedures - Dilation and Curettage, AMERICAN PREGNANCY
ASSOCIATION, www.ameficanpregnancy.org/unplannedpregnancy/surgicalabortions.html (last
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performed after fourteen weeks, generally requires that the provider insert a
synthetic dilator into the cervix for twenty-four hours prior to the procedure,
which is then followed by the insertion of cone-shaped rods to continue the
dilation process.167 Once the woman is dilated, the provider places a tube into
the uterus to suction out the majority of the fetal tissue, and then uses a
curettage to scrape out any remaining contents. 68 Due to the increased risk
to the woman during a D&E, it is usually performed in a hospital setting.
169
The safer and less invasive termination options offered by NIPD may make
women more willing to engage in selective termination based on the genetic
characteristics of their fetuses.
Further, early in the pregnancy, women may find an abortion more
tolerable emotionally. Early in the first trimester, women have had less time
to bond with the fetus or acclimate to being pregnant. The pregnancy may
not feel "real" at that point. Many women wait until after 12-13 weeks to
publicly announce their pregnancy, and are not physically showing their
pregnancy until the end of the first trimester. 70 Many women may feel that
the fetus has not developed to the point of becoming a "baby" by seven
weeks, which may make abortion less psychologically traumatic at that
time.17' By fifteen weeks when amniocentesis becomes available, the
pregnancy and the fetus have developed significantly. Women who undergo
an amniocentesis generally have decided that they want a baby, but they are
visited Aug, 3, 2011). Surgical abortions performed in the first trimester (prior to 13 weeks),
known as suction curettage abortions, generally occur in a clinic or physician's office under
local anesthesia. UCSF MEDICAL CENTER, supra note 162. The physician inserts a tube into
the vagina, through the cervix and uses suction from an electrical machine to empty the
woman's uterus. Id. Such an abortion could occur immediately after CVS, but since CVS is
much less common than amniocentesis, the majority of abortions that result from prenatal
genetic testing occur in the second trimester. Surgical Abortion Procedures - Dilation and
Evacuation, AMERICAN PREGNANCY ASSOCIATION, www.americanpregnancy.org
/unplannedpregnancy/surgicalabortions.html (last visited Aug, 3, 2011) [hereinafter Surgical
Abortion Procedures - Dilation and Evacuation].
167. Surgical Abortion Procedures - Dilation and Evacuation, supra note 166.
168. Id.
169. Id.
170. When to Announce Your Pregnancy, BABYCENTER.COM, http://www.baby
center.com/0 when-to-announce-your-pregnancy_10349769.bc (last visited April 15, 2012)
(discussing the end of the first trimester as a "common time" for women to announce their
pregnancy); Glade B. Curtis and Judith Schuler, YOUR PREGNANCY WEEK BY WEEK 89, 116,
155, 181(5th Ed. 2004) (stating "you still probably won't 'show' at seven weeks, "you still
may not show much" at ten weeks, "your pregnancy may not be obvious to other people when
you wear regular street clothes" at fourteen weeks, and "you are showing more now and have
an obvious swelling in your lower abdomen" at seventeen weeks)
171. Hall et al., supra note 102, at 249.
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concerned about the risk of disease or disorder. 172 For nearly four months
leading up to the testing, the woman has been thinking about the pregnancy
and bonding with the fetus. She is most likely showing and has probably
shared the news of her pregnancy with others. All of these factors may make
termination of an otherwise wanted pregnancy much more difficult.
The timing of NIPD may also change the calculus regarding what
information is "actionable" with respect to selective abortion by broadening
the scope of genetic conditions for which a pregnant woman would test.
173
The emotional and physical hardships associated with having a second
trimester abortion or pregnancy loss may cause many women to either avoid
IPD or to significantly limit the number of conditions for which they would
test. 174 However, the availability of diagnostic genetic information at a time
when a medical abortion is still possible may significantly lower many
women's threshold for prenatal genetic testing and expand the reasons for
which they would selectively abort, resulting in an increase in pregnancy
terminations overall. 7 5 For instance, parents who would not abort an
otherwise wanted child at 18 or 20 weeks, because they preferred a different
sex, may be more willing to do so early in the first trimester, thereby
contributing to "specification creep."
' 176
More than any other advance in reproductive technology, NIPD has the
potential to transform the way we think about pregnancy and our
reproductive decision-making. No single feature of NIPD in isolation would
make it revolutionary, rather it is the combination of factors and their
interrelatedness that will be transformative. NIPD's capacity to offer
significant amounts of genetic information to prospective parents early in the
pregnancy in a safe and relatively easy manner will contribute to physicians
routinely offering it to all pregnant women as the standard of care. 7  While
non-invasiveness is arguably the most important factor, the breadth of
conditions for which testing will be possible and the early detection date will
also increase both the use of diagnostic prenatal testing, as well as the
potential reasons for fetal termination. 178 As Hall et al. suggest, "[m]ore
172. Julie Chevalier Sapp et al., Ambivalence Toward Undergoing Invasive Prenatal
Testing: An Exploration ofIts Origins, 30 PRENATAL DIAGNOSIs 77, 77-82 (2010).
173. de Jong et al., supra note 80, at 274.
174. Smith et al., supra note 27, at 632-33.
175. de Jong et al., supra note 80, at 274; Benn & Chapman, supra note 94, at 2155;
Kooij, supra note 99, at 167-68.
176. Smith et al., supra note 27, at 632-33; Wright, supra note 7, at 29.
177. Chachkin, supra note 124, at 24-38.
178. de Jong et al., supra note 80, at 274.
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generalized use of non-invasive testing could facilitate selective terminations
of pregnancy in a range of conditions hitherto not diagnosed prenatally and
where the arguments for and against termination may not have sufficiently
received scrutiny."' 179 While NIPD offers significant benefit over existing
reproductive genetic testing, its widespread use raises concerns regarding its
impact on patients, providers, and society as a whole. Medical ethicists and
sociologists have begun to examine the implications of widespread NIPD
use, 180 but the legal literature largely remains silent on both the short and
long term challenges raised by NIPD use and the ways in which law and
policy can be used to address them. 18 Part III will examine in depth two
distinct challenges raised by the initial implementation of NIPD and offer a
potential solution.
III. INITIAL IMPLEMENTATION CONCERNS
Prior to widespread commercialization and integration of NIPD into
prenatal care, two challenges must be addressed. 82 First, providers must
decide what tests to offer. By removing the risks associated with current
forms of prenatal diagnostic testing, NIPD lowers the threshold for
appropriate genetic testing. However, the accuracy and reliability of many
genetic tests remain unproven, while other tests offer little clinical benefit.1
83
Unfortunately, few obstetricians have sufficient training in genetics or
179. Alison Hall, Adam Bostanci & Stephen John, Ethical, Legal and Social Issues
Arising from Cell-Free Fetal DNA Technologies. Appendix III to the Report: Cell-Free Fetal
Nucleic Acids for Non-Invasive Prenatal Diagnosis, PHG FOUNDATION 1 (2009), available al
http://www.phgfoundation.org/search/?q=Ethicalpercent2C+Lega+and+Social+Issues+Arisin
g+from+Cell.
180. Benn & Chapman, supra note 94, at 2155; Peter Benn & Audrey R. Chapman,
Ethical Challenges in Providing Non-invasive Prenatal Diagnosis, 22 CURRENT OPINIONS IN
OBSTETRICS & GYNECOLOGY 128 (2010); Hall et al., supra note 102; Schmitz et al., supra note
81, at 165; Dagmar Schmitz et al., An Offer You Can't Refuse? Ethical Implications of Non-
Invasive Prenatal Diagnosis, 10 NAT. REV. GENETICS 515 (2009); Vardit Ravitsky, Non-
Invasive Prenatal Diagnosis: An Ethical Perspective, 10 NAT. REV. GENETICS 733, 733
(2009); de Jong et al., supra note 80, at 234; Newson, supra note 75, at 103; Smith et al.,
supra note 27, at 631.
181. Chachkin, supra note 124, at 9; Hank Greely & Jaime King, The Coming
Revolution in Prenatal Genetic Testing, 23 PROFESSIONAL ETHICS REP. 1 (2010).
182. Hall et al., supra note 102, at 249.
183. Gail H. Javitt, Policy Implications of Genetic Testing: Not Just for Geneticists
Anymore, 13 ADVANCES IN CHRONIC KIDNEY DISEASE, 178, 179 (2006).
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available time to identify those tests appropriate for NIPD. 84 Secondly,
providers must decide what information to give patients regarding the tests
offered. The advent of NIPD testing will place significant strain on our
current practice of genetic counseling and informed consent for prenatal
genetic testing, and will require a new paradigm of informing patients of the
risks and benefits of engaging in prenatal genetic testing. Both the challenges
involved in determining which tests to offer patients and what information to
provide them with have the potential to create confusion, misinformation and
problems for prospective parents and prenatal care providers attempting to
use NIPD. This article proposes a single solution to both issues in the form of
panels of genetic tests designated as meeting a threshold level of analytic and
clinical validity and encompassing disorders with similar characteristics for
genetic counseling purposes.
A. What Tests to Offer?
As our ability to offer a range of genetic test expands, minimum
standards for tests offered through NIPD panels should be established. 185 As
noted above, physicians have an ethical obligation to avoid engaging in a
medical procedure for which the risks outweigh the benefits. 186 Historically,
this obligation has limited prenatal genetic testing to a handful of well-
researched, severe genetic conditions. For NIPD, the balance of risks and
benefits changes significantly. In the absence of a significant risk to the fetus
or mother, the benefit of added information-even imperfect information-
will appear to outweigh the risks of testing. Unfortunately, with respect to
many genetic tests, imperfect information abounds.' 87 Neither the public nor
physicians are well equipped to analyze the complexities of genetic
interactions, laboratory testing methods, or the statistical risk factors required
to determine the usefulness of many genetic tests.188 As a result, the risk of
false or misleading information may frequently go unacknowledged. In the
realm of NIPD, this can have devastating results in the form of the
184. Id. at 180; Marieke J.H. Baars et al., Deficiency of Knowledge of Genetics and
Genetic Tests Among General Practitioners, Gynecologists and Pediatricians: A Global
Problem, 7 GENETICS MED. 605, 605-10 (2005).
185. Benn & Chapman, supra note 94, 2155.
186. Tom L. Beauchamp & James F. Childress, PRINCIPLES OF BIOMEDICAL ETHICS 166
(5th ed. 2001).
187. Javitt, supra note 183, at 179; Benn & Chapman, supra note 94, at 2155.
188. Benn & Chapman, supra note 94, at 2155.
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termination of an unaffected child, the birth of a child with a condition
thought to be excluded, unnecessary anxiety, or general misinformation. 89
According to the National Institutes of Health Secretary's Advisory
Committee on Genetic Testing (SACGT), the benefits and risks of using any
genetic test should be evaluated across four criteria: analytic validity, clinical
validity, clinical utility, and social consequences.'" Analytic validity is "how
well a test measures the property or characteristic it is intended to
measure."' 9 1 Clinical validity indicates how well the test results correspond
to the presence or absence of a clinical disease or predisposition.'92 Clinical
utility refers to the usefulness of the information provided by the test to the
patient or physician.' 93 Finally, even analytically and clinically valid tests
with high clinical utility may present negative social consequences in the
form of discrimination for individuals receiving the test or living in society
with stigmatized conditions. 194 Each of these four evaluative criteria should
factor into a physician's decision to use a certain test for NIPD.
With respect to genetic tests, analytic validity means that the test
accurately identifies the targeted sequence of nucleic acids. 95 In judging the
analytic validity of a genetic test, providers currently have little information
to go on. Regulating access to genetic tests based on analytic validity is
typically left to the Center for Medicare and Medicaid Services (CMS) and
the Food and Drug Administration (FDA), yet neither agency has taken an
authoritative stance with respect to regulating genetic tests.' 96 Through the
Clinical Laboratory Improvement Amendments (CLIA), Congress granted
CMS the authority to regulate diagnostic tests performed in clinical
laboratories. 97 CMS requires laboratories that perform clinical tests within
more complex areas of expertise, such as microbiology or diagnostic
immunology, to obtain a specialty certification that requires minimum scores
189. Smith et al., supra note 27, at 632.
190. NATIONAL INSTITUTES OF HEALTH, ENHANCING THE OVERSIGHT OF GENETIC TESTS
15, http://oba.od.nih.gov/SACGHS/sacgtdocuments.html#GTDOC002.
191. Id.
192. Id. at 11.
193. Id. at 12.
194. Id. at 20.
195. Id. at 15.
196. DEP'T OF HEALTH AND HUMAN SERVS., U.S. SYSTEM OF OVERSIGHT OF GENETIC
TESTING: A RESPONSE TO THE CHARGE OF THE SECRETARY OF HEALTH AND HUMAN SERVICES,
REPORT OF THE SECRETARY'S ADVISORY COMMITTEE ON GENETICS, HEALTH AND SOCIETY 29
(April 2008).
197. 42 U.S.C. § 263a(b) (2006) (requiring all laboratories that solicit or accept
materials derived from the human body for laboratory examination to be certified).
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on proficiency tests and quality assurance measures, as well as minimum
training requirements for personnel. 98 However, CMS has not created a
specialty certification for genetic testing.' 99 Accordingly, there is, at best,
little oversight of the analytic validity of genetic tests provided by any
specific laboratory. 2 °
In addition to CMS, the FDA also has the ability to regulate commercial
use of any genetic test that qualifies as a medical device. 20 1 To the extent that
a genetic test used for NIPD qualifies as a medical device under the Food
and Drug Modernization Act by providing diagnostic information about a
fetus, the FDA has the authority to determine whether the test meets safety
and efficacy requirements needed for commercial use. 20 2 To date, the FDA
has not exercised this authority to regulate most genetic tests.
203
However, the agency seems more likely to begin regulating the safety
and efficacy of genetic tests in the near future. In July 2010, the FDA held
hearings to receive comments from stakeholders regarding how the
government should oversee the validity and accuracy of genetic tests and
other in vitro diagnostics. 204 As genetic testing becomes more prevalent in
commercial markets, DNA microarrays are more widely used to test for
multiple genetic mutations, and geneticists use complex statistical algorithms
to evaluate those results in order to provide patients with diagnostic
198. 42 C.F.R. §§ 493.801-493.807 (2010).
199. Javitt, supra note 183, at 178-79.
200. GAIL H. JAVTI" & KATHY HUDSON, PUBLIC HEALTH AT RISK: FAILURES IN
OVERSIGHT OF GENETIC TESTING LABORATORIES 4 (2006), available at
http://www.dnapolicy.org/images/reportpdfs/PublicHealthAtRiskFinalWithCover.pdf.
201. 21 U.S.C. § 321(h) (2006). Section 201(h) of the Food, Drug and Cosmetic Act
defines a medical device as "an instrument, apparatus, implement, machine, contrivance,
implant, in vitro reagent, or other similar or related article, including any component, part, or
accessory, which is... (2) intended for use in the diagnosis of disease or other conditions, or
in the cure, mitigation, treatment, or prevention of disease, in man or other animals." Id.; see
also U.S. FOOD & DRUG ADMIN. ET AL., DRAFT GUIDANCE FOR INDUSTRY, CLINICAL
LABORATORIES, AND FDA STAFF: IN VITRO DIAGNOSTIC MULTIVARIATE INDEX ASSAYS 3
(2007), available at http://www.fda.gov/cdrh/oivd/guidance/1610.pdf.
202. Gregorio M. Garcia, The FDA and Regulation of Genetic Tests: Building
Confidence and Promoting Safety, 48 JURIMETRICS J. 217, 226 (2008).
203. Baruch et al., supra note 149, at 7. The FDA does regulate certain components
used in in-house laboratory tests, known as analyte specific reagents (ASRs), so that
healthcare providers would know how the tests were being validated. See FOOD & DRUG
ADMIN., supra note 201, at 3 (citing 21 C.F.R. §§ 809.10(e), 809.30, 864.4020 (2007)). See
generally, Garcia, supra note 202.
204. Alla Katsnelson, Consumer Genetic Testing in the Hotseat: A Week of Hearings
Sows Uncertainty for the Fledgling Consumer Genomics Industry, NATURE (July 29, 2010),
http://www.nature.com/news/2010/100729/full/news.2010.382.html.
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information on a range of conditions, the FDA will likely take a more active
role in regulating the analytic validity of genetic tests.20° However, how the
FDA will go about regulating these multivariate arrays remains to be seen
and will likely require deviation from its current protocols regarding medical
devices.2 °6 The FDA did indicate that the level of regulation required will
depend on the risk the specific test poses to the consumer, including the
potential harm from an incorrect result.20 7 This statement may indicate that
the FDA intends to regulate access to genetic tests based on their usage as
well as their accuracy.
While FDA guidance on analytic validity will be a step in the right
direction, it will do little more than provide a minimum requirement for
decisions regarding reproductive genetic testing. In examining a genetic
test's overall efficacy, the FDA will hopefully also include information on
the test's clinical validity. In general, genetic tests have high analytic
validity, meaning they are highly accurate in measuring the presence of the
particular DNA sequence of interest, but their clinical validity or the ability
of the test to accurately predict the development of a condition of interest to
the patient is less reliable. 208 Clinical validity analysis will reveal how
closely associated the tested genetic sequence is with the onset of the disease
or condition in question. In other words, if an individual has the gene
sequence targeted by the genetic test, how likely is it that he or she will have
the genetic disease or condition?
Information on this genotype/phenotype association is essential for
deciding whether to offer a genetic test, and, unfortunately, it can be affected
by many factors. First, a particular allele may be only one part of a
multifactorial predisposition to disease; other genetic sequences or
environmental factors and their interaction may also contribute to the
presentation of the disease phenotype. 20 9 Second, an allele may have low
penetrance, meaning that the presence of the disease genotype does not
always result in the disease phenotype. 21 Low penetrance can even occur in
205. Id.
206. Id.
207. Id.
208. NATIONAL INSTITUTES OF HEALTH, supra note 190, at 15.
209. Francis S. Collins et al., U.S. Nat'l Human Genome Research. Inst., A Vision for
the Future of Genomics Research: A Blueprint for the Genomic Era, 422 NATURE 835, 840
(2003).
210. Human Genome Project, Evaluating Genetic Tests: Some Considerations,
GENOMICS.ENERGY.GOV (Sept. 19, 2008), http://www.ornl.gov/sci/techresources/Human
Genome/resource/testeval.shtml.
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single gene disorders.211 Finally, epigenetic factors, which are also controlled
by other genes and the environment, can affect whether a gene is turned "on"
or "off', which would determine the phenotype.212 Any one of these factors
could cause an individual to receive a positive test result from a test with
high analytic validity, but have a child who does not present with the
phenotype of the tested for condition. A test with low clinical validity could
cause a woman to abort a fetus that would never develop the genetic disease,
causing needless heartache and loss. 213 While the FDA is determining how to
regulate genetic tests, providers will be left to make choices on their own
with little guidance. Unfortunately, most have little training in genetics and
sparse understanding of the numerous factors that can affect the presentation
of a genetic disorder.214 Further, to properly make choices regarding which
tests to offer, providers will have to know these factors for a wide array of
genetic tests.
Rather than providers learning this information, biotechnology
companies eager to get into the prenatal testing market are likely to make
choices of what tests to offer for providers by creating genetic testing
protocols. Existing companies, like Counsyl and 23&Me, currently offer pre-
packaged genetic testing protocols that can be used for reproductive
decision-making.1 5 Counsyl, a genetic testing company in Silicon Valley,
sells the Universal Genetic Test that enables prospective parents to know if a
future child would be at risk for a recessive genetic disorder because both
parents carry recessive alleles associated with the disorder.216 The Universal
Genetic Test offers diagnostic testing for over 100 of the most common
recessive genetic disorders.217 23&Me also offers carrier screening for
twenty-four genetic disorders to enable prospective parents to know if their
211. Id. BRCA 1 and 2 are highly, but incompletely, penetrant, meaning that they
cause a significantly increased risk for breast cancer, but do not guarantee the individual will
contract the disease. Id. Scientists hypothesize that other mutations and environmental factors
contribute to development of the disease. Id.
212. Elizabeth Pennisi, Behind the Scenes of Gene Expression, 10 Sol. 1064, 1064-67
(2001).
213. King, supra note 88, at 336; Garcia, supra note 202, at 232.
214. NEIL F. SHARPE & RONALD F. CARTER, GENETIC TESTING: CARE, CONSENT, AND
LIABILITY 209 (2006).
215. Counsyl, COUNSYL.COM, https://counsyl.com/ (last visited Aug. 11, 2011);
Health, 23&ME.coM, https://www.23andme.com/health/ (last visited Aug. 11, 2011).
216. COUNSYL.COM, supra note 215.
217. Id.
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offspring are at risk of inheriting a genetic disease.218 In addition, 23&Me
sells a range of genetic testing protocols to satisfy consumer interest,
including panels on ancestry testing, disease risk, and drug response.2 19 Often
the genetic tests offered as part of these protocols do not have the highest
clinical validity, but instead offer imperfect information on conditions likely
to be of interest to consumers.
DTC genetic testing companies are not subject to guidelines from the
American Society for Reproductive Medicine (ASRM) or any other
professional society regarding the appropriate uses of NIPD. Further, they do
not owe their customers the same ethical and legal obligations that
physicians owe their patients. In fact, their ethical obligations are almost
entirely owed to their shareholders, which may incentivize the sale of tests
for genetic conditions of great interest to the population, despite their lack of
clinical validity or utility. 220  Given these risks, the challenges of
communicating genetic risk information, the limited accuracy of certain
genetic tests, and the extreme potential consequences of providing risk
information in a prenatal context, some states may require physician
involvement in NIPD testing, as many do with other laboratory tests.
221
However, DTC companies have largely side-stepped that requirement by
keeping physicians on staff to prescribe tests and offer limited forms of
counseling.222 Until the FDA provides a meaningful national approach to
certifying the safety and efficacy of DTC genetic tests, state governments
may be the only line of defense patients and consumers have against
inaccurate or low utility tests. At a minimum, states should ensure that
prospective parents receive NIPD for all medical tests under the guidance of
an unbiased medical provider by passing laws or regulations that permit
218. Health-Carrier Status, 23&ME.COM, https://www.23andme.com/health/carrier/.
(last visited April 4, 2012).
219. Ancestry, 23&ME.coM, https://www.23andme.com/ancestry/ (last visited April 4,
2012); Health, 23&ME.coM https://www.23andme.com/health/ (last visited April 4, 2012).
220. See generally John R. Boatwright, Fiduciary Duties and the Shareholder
Management Relation: Or, What's So Special about Shareholders? 4 BuS. ETHICS Q. 393
(1994).
221. CAL. Bus. & PROF. CODE § 1288 (2010). California was the first state to challenge
DTC genetic testing companies by enforcing laboratory standards and requirements that
patients receive tests through a licensed physician. Letter from California Health and Human
Services Agency to Phil Robinson (June 9, 2008) (on file with author); GENETICS AND Pu.
POLICY CTR., SURVEY OF DIRECT-TO-CONSUMER TESTING STATUTES AND REGULATIONS (2007).
222. Alexis Madrigal, 23andMe to California: We're Not Ceasing or Desisting,
WIRED SCIENCE (June 24, 2008, 9:39AM) http://www.wired.com/wiredscience
/2008/06/23andme-were-no/.
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NIPD only under the guidance of an independent physician. While a
physician may not have perfect clinical validity information, they do have a
fiduciary duty to act in the patient's best interest.
Once clinical validity information becomes available, providers will be
better equipped to determine the clinical utility of the test. The clinical utility
of a genetic test measures the usefulness of the information for physicians
and patients in making treatment choices. Clinical utility ranges from
extremely high when the test results clearly dictate treatment protocol to very
low if the results would not change the treatment protocol at all.223 Many
genetic tests will have a mid-range utility as they will inform a treatment
decision, but other factors will also play a role. In the case of NIPD, test
results can lead to prenatal treatment of the pregnant woman or fetus,
preparation of the parents and physicians for the birth and care of an affected
child, or a decision to terminate. Physicians should derive the clinical utility
of a specific test from its known analytic and clinical validity, and use that
information to determine which tests to include in NIPD. For example, they
should avoid use of genetic tests when the analytic or clinical validity is so
low as to negate the clinical utility of the test.
Finally, individual physicians may consider the social consequences in
determining whether to offer certain tests in the prenatal context. For
instance, some physicians may opt not to offer NIPD for non-medical sex
selection, because they do not believe parents should terminate a fetus based
on such information. While such a practice will not prevent prospective
parents from accessing NIPD for such a reason, physicians may elect to
exercise their personal autonomy in refusing to offer certain tests based on
personal beliefs or potential social consequences. To this end, the Oklahoma
legislature recently passed, over gubernatorial veto, a law prohibiting
wrongful birth actions and in doing so protected physicians from liability for
failing to disclose information that they believe might lead prospective
parents to abort a fetus.224 Twelve other states have similarly prohibited
225
wrongful birth actions either by state court decisions or legislative action.
223. NATIONAL INSTITUTES OF HEALTH, supra note 190, at 12.
224. H.B. 2656, Reg. Sess. (Okla. 2010). See also Associated Press, Oklahoma Senate
Overrides Abortion Restriction Vetoes, BOSTON HERALD, April 27, 2010, available at
http://www.bostonherald.com/news/national/southwest/view.bg?articleid = 1250502.
225. See Jillian T. Stein, Backdoor Eugenics: The Troubling Implications of Certain
Damages Awards in Wrongful Birth and Wrongful Life Claims, 40 SETON HALL L. REV. 1117,
1131-32 n.92-93 (2010) (citing Etkind v. Suarez, 519 S.E.2d 210, 212 (Ga. 1999); Grubbs v.
Barbourville Family Health Ctr., P.S.C., 120 S.W.3d 682, 689 (Ky. 2003); Taylor v. Kurapati,
600 N.W.2d 670, 691 (Mich. Ct. App. 1999); Wilson v. Kuenzi, 751 S.W.2d 741, 746 (Mo.
1988); Azzolino v. Dingfelder, 337 S.E.2d 528, 537 (N.C. 1985); Idaho Code Ann. § 5-334(1)
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While most states do not have laws that could protect physicians from failing
to disclose information they believe may lead prospective parents to seek an
abortion, all states permit physicians to retain the ability to deny patients
medical procedures they do not wish to perform.226 As a result, some prenatal
care providers may decline to offer NIPD for social reasons, which may limit
access for certain portions of the population.
Unfortunately, understanding the analytic validity, clinical validity,
clinical utility, and social consequences of a genetic test requires extensive
knowledge and understanding of the underlying genetic disease, its
characteristics, the cultural implications of the specific disease or condition,
and the specific nature of the genetic testing process, which may be beyond
the knowledge and understanding of many obstetricians seeking to determine
whether a test is appropriate for NIPD. In addition, even physicians who
have mastered this information may be unable to effectively communicate it
in a manner that enables their patients to make an informed choice regarding
whether they want to test their fetus for such a condition.
B. How Should Providers Inform Patients?
Historically, the main justification for engaging in prenatal genetic
screening and testing is to promote the reproductive autonomy of prospective
227parents. The decision to engage in prenatal screening or diagnosis carries
significant weight and can have life-altering results. Establishing a method of
informed consent for NIPD that adequately respects the range of prospective
parents' desires for information while balancing the practical constraints of
(LEXIS through 2009 Reg. Sess.); Ind. Code Ann. § 34-12-1-1 (LexisNexis, LEXIS through
2009 1st Reg. Sess. and 2009 Special Sess.); Mich. Comp. Laws Serv. § 600.2971(1)
(LexisNexis, LEXIS through P.A. 2 of 2010 Legis. Sess.); Minn. Stat. § 145.424(1) (LEXIS
through 2009 Reg. Sess.); Mo. Ann. Stat. § 188.130 (West, Westlaw through 95th Gen.
Assembly, Ist Reg. Sess.); N.D. Cent. Code § 32-03-43 (LEXIS through 2009 Legis. Sess.);
42 Pa. Cons. Stat. Ann. § 8305(a) (West 2007); S.D. Codified Laws § 21-55-2 (Westlaw
through 2009 Legis. of 84th Sess.); Utah Code Ann. § 78B-3-109 (LEXIS through 2009 1st
Special Sess.)).
226. See American College of Obstetricians and Gynecologists, ACOG Committee
Opinion No. 385: The Limits of Conscientious Refusal in Reproductive Medicine, 110
OBSTETRICS & GYNECOLOGY 1203, 1203-08 (2007); REPORT OF THE COUNCIL ON ETHICAL
AND JUDICIAL AFFAIRS, CEJA REPORTS 6-A-07, AMERICAN MEDICAL ASSOCIATION (2007),
available at www.ama-assn.orglresources/doc/ethics/ceja_recs_6aO7.pdf (last visited Aug. 11,
2010).
227. Schmitz et al., supra note 180, 515-16; SHARPE & CARTER, supra note 214, at
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physicians' and society's interests is of utmost importance, but will not be
228
easy.
The law generally requires health care professionals to inform the patient
of the risks, benefits and alternatives to a proposed treatment and obtain her
consent prior to commencing any treatment. 29 Ethical guidelines for prenatal
genetic testing also recognize the importance of ensuring not only that the
patient receives information on all relevant medical facts, but also that the
patient engages in active decision-making and exercises a free choice to have
testing. 3 ° Many scholars have expressed concern that without significant
reconsideration of our informed consent procedures for prenatal diagnostic
testing, many pregnant women will not make informed choices regarding the
use of NIPD generally, testing for specific conditions, or selective
abortion. The following sections examine the current informed consent
practices used for reproductive genetic testing, and why those practices are
not well suited to informed consent for NIPD. I then propose a new model of
informed consent for NIPD.
1. Current Informed Consent Practices in Reproductive Genetics
With respect to current prenatal genetic services, informed consent
232generally occurs in a two-step process. First, the pregnant woman decides
whether to engage in prenatal screening for risk factors associated with
Down syndrome and other genetic and chromosomal disorders.233 To make
this decision, physicians and genetic counselors are advised to provide
women with information on the available methods of prenatal diagnosis; the
difference between screening (via ultrasound and maternal serum analysis)
and diagnostic testing (via CVS or amniocentesis); the risks and benefits of
228. Zuzana Deans & Ainsley J. Newson, Should Non-Invasiveness Change Informed
Consent Procedures for Prenatal Diagnosis?, 19 HEALTH CARE ANALYSIS 122, 130-31
(2010).
229. Jaime S. King & Benjamin Moulton, Rethinking Informed Consent: The Case for
Shared Medical Decision-Making, 32 AM. J. L. MED. 429,439 (2006).
230. SHARPE & CARTER, supra note 214, at 207; CODE OF PROFESSIONAL ETHICS OF
THE AMERICAN COLLEGE OF OBSTETRICIANS AND GYNECOLOGISTS § I at 5 (2008); AMA CODE
OF MEDICAL ETHICS § 2.12 (1994).
231. Newson, supra note 75, at 105; Hall et al., supra note 102, at 249-50; Schmitz et
al., supra note 180; Ananda van den Heuvel et al., Will the Introduction of Non-Invasive
Prenatal Diagnostic Testing Erode Informed Choices? An Experimental Study of Health Care
Professionals, 78 PATIENT EDUC. & COUNSELING 24,24 (2009).
232. 1 will focus on the process for prenatal screening followed by amniocentesis,
rather than that of CVS, as the majority of women pursue this process.
233. de Jong et al., supra note 80, at 273.
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various techniques, including the risk of pregnancy loss associated with
diagnostic testing; the timing of the procedures; details of the diseases and
conditions for which the procedure screens or tests; the frequency of
abnormal, false positive, and false negative results; the frequency of the need
for repeat testing; the possibility that certain abnormalities may go
undetected; and for newer procedures, a detailed explanation of their
234
uncertainty and experimental nature. Prior to engaging in prenatal
screening, physicians should discuss with pregnant women which conditions
they would like to be tested for and the different ways they could use the
information, should they discover their fetus was at elevated risk for a
genetic or chromosomal disorder. 235 This can have a variety of results. Some
women will want as much information as possible. Others will want
information, but decline screening because they would not want to undertake
the risk of a miscarriage to receive diagnostic results should they screen high
risk.236 Others might decide that knowing their fetus was at higher risk might
increase their anxiety levels for the rest of the pregnancy and opt against
screening. Others still may want probabilistic information offered by a
screening test, but not want to know for certain the status of her fetus,
preferring instead to preserve hope that her child will not have a particular
condition.237 Some women, who would not consider terminating a fetus,
might still want definitive diagnostic information to enable them to prepare
for a potentially affected pregnancy. What is important is that pregnant
women are given the opportunity to think through the implications of having
risk information prior to engaging in prenatal screening.
Unfortunately, empirical research suggests that in many instances
pregnant women do not receive any or all of this information prior to
238prenatal screening. In practice, women often receive only limited
234. SHARPE & CARTER, supra note 214, at 209.
235. Id. at 211.
236. E. Garcia et al., Reconsidering Prenatal Screening: An Empirical-Ethical
Approach to Understand Moral Dilemmas as a Question of Personal Preference, 35 J. MED.
ETHICS 410, 412 (2009).
237. Deans & Newson, supra note 228.
238. Schmitz, et al., supra note 180, at 733; Nancy Press & C. H. Browner, Risk,
Autonomy, and Responsibility: Informed Consent for Prenatal Testing, 25 HASTINGS CTR.
REP. S9, SI 1-12 (1995); Cate Nagle et al., Exploring General Practitioners' Experience of
Informing Women About Prenatal Screening Tests for Foetal Abnormalities: A Qualitative
Focus Group Study, 8 BMC HEALTH SERVICES RES. 114, 118-19 (2008), available at
http://www.biomedcentral.com/1472-6963/8/114; H-H Chiang et al., Informed Choice of
Pregnant Women in Prenatal Screening Tests for Down's Syndrome, 32 J. MED. ETHICS 273,
274-75 (2006).
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information before prenatal screening and due to the limited risks of the
blood test, are rarely asked to provide informed consent. 239 As a result,
women often remain unaware that screening may well lead to decisions
240
regarding IPD and potentially pregnancy termination.
In most cases, women receive prenatal genetic screening and then, only
if they screen high risk, do they enter the second step of informed consent
and genetic counseling. 241 If the fetus screens high-risk for a certain
condition, providers can focus their discussion on that specific condition and
provide extensive information on the child's prognosis. In addition, providers
will also counsel prospective parents regarding the option of IPD to obtain
more definitive information about the health of her fetus and the risk of
miscarriage. At this stage, the importance of providing patients with clear,
comprehensive information regarding the genetic condition of interest, the
risks of testing, and time to reflect on it cannot be overstated. Due to the
rarity of these disorders, many prospective parents will have little to no
knowledge of the disorder or its impact, and therefore they will be "almost
entirely dependent on their counselors for information about disabilities. 242
Unfortunately, many health professionals lack sufficient knowledge or
resources to provide adequate information to prospective parents, especially
as prenatal screening is increasingly performed as part of primary or
obstetrical care, rather than via a geneticist. 243 An under-informed provider
can greatly hinder a patient's decision-making capacity.
244Timing is also important to the informed consent process. A recent
study on informed consent practices in prenatal testing revealed that 94
percent of practitioners surveyed believed that the offer and procedure of
IPD should occur on different days. 245 This approach gives prospective
parents the opportunity to reflect on their personal values and preferences
prior to making a decision about whether to pursue further prenatal testing to
receive a definitive result. Even with its flaws, prenatal screening followed
239. Benn & Chapman, supra note 94, at 2154.
240. See id; Valerie Seror & Yves Ville, Prenatal Screening for Down syndrome:
Women's Involvement in Decision-Making and Their Attitudes to Screening, 29 PRENATAL
DIAGNOSIS 120, 126-27 (2009).
241. Schmitz et al., supra note 180, at 733.
242. SHARPE & CARTER, supra note 214, at 208 (quoting THE ROYAL COMMISSION ON
NEW REPRODUCTIVE TECHNOLOGIES, 2 PROCEED WITH CARE: FINAL REPORT OF THE ROYAL
COMMISSION ON NEW REPRODUCTIVE TECHNOLOGIES 780-82 (Ottawa: Minister of
Government Services 1993)).
243. Id. at 209.
244. Deans & Newson, supra note 228.
245. van den Heuvel, et al., supra note 231, at 27.
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by IPD enhances the ability of genetic counselors and prenatal care providers
to counsel patients regarding reproductive genetic testing. The minimal risk
and non-diagnostic result associated with prenatal screening reduces the
requirement for extensive counseling on the wide array of disorders screened
for, but while still leaving clinicians the opportunity to provide extensive
information on a single high risk disorder prior to diagnostic testing.
2. Informed Consent for NIPD
NIPD will not offer the same opportunities. Since its discovery, a
handful of scholars have debated the effect widespread availability of NIPD
will have on informed consent for prenatal genetic testing and reproductive
autonomy. 246 Opinions range from the claim that NIPD represents an "ethical
imperative" 247 required to promote reproductive autonomy to the concern
that NIPD "might pose serious threats to the autonomous decision making of
the pregnant woman248 to the notion that NIPD need not alter informed
consent processes for prenatal genetic testing at all.
249
Without question, NIPD offers significant benefits for prospective
parents. First, by removing the risk associated with IPD, NIPD may reduce
the ambivalence patients feel with respect to reproductive genetic testing,
and therefore facilitate patients' ability to make decisions based entirely on
their personal values and preferences. 250 Further, NIPD will permit genetic
counselors to focus on discussion of risks associated with the relevant
genetic disorders, rather than those associated with IPD, improving the
efficiency of counseling.251 Second, providing pregnant women with more
information about the genetic make up of their fetus will in many cases
enhance their reproductive autonomy by expanding the range of conditions
that can factor into their decisions. Finally, the timing of NIPD also increases
women's options and in turn bolsters her reproductive autonomy. In the
instance that a fetus is affected by a genetic condition, being able to undergo
246. Wright, supra note 7; Benn & Chapman, supra note 94; Benn & Chapman, supra
note 180; Hall et al., supra note 102; Schmitz et al., supra note 81; Schmitz et al., supra note
180; Ravitsky, supra note 180; de Jong et al., supra note 80; Newson, supra note 75; Smith et
al., supra note 27.
247. Ravitsky, supra note 180, at 733.
248. Schmitz, supra note 180, at 733.
249. de Jong et al., supra note 80, at 273.
250. van den Heuvel et al., supra note 231, at 27; Elizabeth Dormandy et al., Attitudes
and Uptake of a Screening Test: The Moderating Role of Ambivalence, 21 PSYCHOL. &
HEALTH 499, 500-01 (2006); Hall et al., supra note 102, at 249.
251. Ravitsky, supra note 180, at 733.
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NIPD as early as nine weeks gestation leaves parents significant time to
gather information on treatment options, life with an affected child, and the
support services available. In contrast, amniocentesis frequently occurs close
to the point of viability, leaving little time for such information gathering. 52
If the pregnant woman decides to continue the pregnancy, she has a greater
amount of time to explore treatment options and prepare for the birth of a
disabled child.253 If she elects to terminate, termination will be safer, easier
to obtain, and may be less emotionally traumatic.2 5 4 Each of these factors
will improve the ability of a pregnant woman to make a choice based on her
feelings about having a child with a specific genetic condition, rather than
other factors that currently must play into the decision.
On the other hand, concerns about NIPD's impact on reproductive
autonomy stem from the probability that informed consent for diagnostic
prenatal genetic testing will shift from a two-step process to a more general
one-step process similar to consent for prenatal screening that compares the
informational benefits of NIPD to the minor discomfort of having your blood
255drawn. One study performed in the UK suggests that in this context
offering NIPD may reduce disclosure, rather than expand it.256 Ananda van
den Heuvel and colleagues surveyed 231 health care professionals involved
in prenatal testing regarding their informed consent practices using vignettes
describing one of three genetic testing situations: IPD, NIPD, and maternal
serum screening for Down syndrome (DSS).2 57 The perceived need for a
written informed consent varied significantly depending upon the type of
test.258 Ninety-six percent of respondents given the IPD vignette believed
that testing should definitely or probably be proceeded by a written consent,
compared to 68 percent for NIPD and 73 percent for DSS. 25 9 Post-hoc
analysis demonstrated that opinions about NIPD consent significantly
differed from consent for IPD, but were similar to those about DSS,
demonstrating that the miscarriage risk associated with IPD may be driving
252. Id.
253. Id. (citing BZGA, EXPERIENCE OF PREGNANCY AND PRENATAL DIAGNOSIS 31, fig.
18 (Ilona Renner ed. 2006)), available at http://www.bzga.de/botmed_13319270.html (finding
that 23.2 percent of women surveyed said prenatal diagnosis would enable planning and
provision of care for the baby in good time in the event of a disability.).
254. Id.
255. Benn & Chapman, supra note 94, at 2155; Schmitz et al., supra note 180, at 515.
256. van den Heuvel et al., supra note 231, at 24.
257. Id. at 25-26. The majority of respondents were female (79.7 percent)
obstetricians (59.3 percent). Id. at 26, tab. 1.
258. Id. at 27. (X2 = 23, df = 2, p =.001).
259. Id.
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perceptions of the need for a formal consent process, rather than the
diagnostic nature of the information contained in the test.2 6 As a result,
practitioners may fail to adequately consider the remaining implications of
261the testing procedures. Patients may make the same mistake. Schmitz et al.
have argued that removing the miscarriage risk will eliminate the
psychological barrier that often forces patients and practitioners to make
critical judgments about the risks and benefits of prenatal genetic
diagnosis.262
Focusing only on the miscarriage risk ignores the fact that receiving
diagnostic genetic information will not benefit all pregnant women. 26' For
some, the information can be "toxic.' ' 264 Prenatal genetic tests, like other
genetic tests, can have significant psychological ramifications. Prospective
parents may experience guilt over passing a disorder to the fetus. They may
feel guilt that their child is not affected, when other family members'
children are. 265 For late onset disorders, like Huntington's Disease, prenatal
testing of a fetus may also reveal that both the fetus and the parent will
develop the disorder in the future, creating both guilt and anxiety for the
prospective parent.2 66 Prenatal genetic testing presents significant social and
psychological risks, including anxiety, depression, and anger, that patients
and providers should not overlook in deciding to test.267 If patients and
practitioners view NIPD as analogous to genetic screening rather than IPD,
then some women will find themselves emotionally unprepared for and
unintentionally facing a decision between termination and carrying an
affected child to term.268 Schmitz and colleagues argue that at this point,
"reproductive autonomy would no longer be realizable, and the main ethical
260. Id.
261. Id. at 25.
262. Schmitz et al., supra note 81, at 165.
263. Suter, supra note 125, at 233.
264. Id.
265. Id. at 237-38 (quoting Gail Geller et al., Genetic Testing for Susceptibility to
Adult-Onset Cancer: The Process and Content of Informed Consent, 277 JAMA 1467, 1471
(1997)).
266. Id. (discussing the phenomenon that many individuals who knew they were at
risk for HD did not want to undergo testing because they did not want to spend their lives
waiting to develop the disorder).
267. Id. at 258-59.
268. Schmitz et al., supra note 81, at 165.
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justification for non-invasive prenatal diagnosis would be reduced to mere
rhetoric.
269
Other researchers have argued that a one-step approach to NIPD
counseling does not necessarily make prenatal genetic counseling more
difficult and ethically problematic. 270 Antina de Jong and colleagues claim
that it is the expansion of the scope of prenatal testing that others assume will
occur under NIPD that raises challenges for informed choice and
reproductive autonomy, not the nature of the test itself.2 71 Therefore if
clinicians offered NIPD for only the conditions currently tested for under the
two-step process of prenatal genetic screening followed by IPD, the
challenges of adequately informing pregnant women are no different for
NIPD than current testing.272 While such an approach would reduce the
potential for false or clinically unclear results, limit the amount of
information and discussion necessary to adequately counsel patients, and
lower the cost of both the procedure and the counseling, 273 the authors make
two assumptions that are not tenable. First, this approach assumes that over
time patients will not demand access to an expanded range of scientifically
274
available genetic tests on which to make reproductive decisions.27 Second,
the approach assumes that health care providers can and do offer all
necessary information on the conditions tested for during the first step of the
two-step process. Empirical evidence does not support this assumption. 275 As
discussed above, clinicians do not provide complete information prior to
screening because doing so would be overly burdensome for them, anxiety
provoking for patients, and potentially unnecessary at the point of screening.
This is especially true when a second opportunity for a more in depth and
particularized discussion exists, should one need to occur. As a result, the
protocols for informing patients in a consistent and complete manner are not
as firmly established as the authors suggest. Even for providers that do offer
information on all conditions screened for in the first stage of informed
consent, a second opportunity for discussion and clarification still exists prior
to making a decision regarding diagnostic testing. NIPD alters this dynamic,
269. Id. (citing V. Seavilleklein, Challenging the Rhetoric of Choice in Prenatal
Screening, 23 BIOETHICs 68 (2009)).
270. de Jong et al., supra note 80, at 273.
271. Id.
272. Id. Dennis Lo has also echoed the sentiment that initially clinicians should limit
NIPD testing to only those well-known and understood genetic disorders prevalent in certain
populations. Lo et al., supra note 3, at 10.
273. de Jong et al., supra note 80, at 274.
274. Id.
275. See generally supra note 230; van den Heuvel et al., supra note 231, at 27.
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and does so in a way that challenges our current informed consent process,
even if used for the limited set of conditions currently screened for.
Providing sufficient information to enable a pregnant woman to make an
informed choice about testing her fetus for numerous genetic conditions will
require significant changes to either step in the current prenatal genetic
testing informed consent process. Limiting the discussion to current practices
276for prenatal genetic screening would be inadequate. However, offering
comprehensive information for all genetic conditions similar to genetic
counseling once an individual has screened high risk for a certain disorder to
all women undergoing NIPD is impractical. First, there are insufficient
numbers of genetic counselors and adequately trained obstetricians to
accomplish this goal27 Second, the amount of time and information required
to adequately counsel patients would make it burdensome on counselors and
278patients as well as prohibitively expensive. Overall, NIPD has the ability
to both improve and impede pregnant women's exercise of reproductive
autonomy. If NIPD is introduced into clinical practice with little
acknowledgment of the challenges it raises for informed choice, many
women may receive genetic information about their fetus that they are
unprepared for and would never have knowingly sought. However, if health
care practitioners, genetic counselors, professional societies, ethicists and
policy makers take this brief opportunity before NIPD becomes normalized
in prenatal care to design informed consent guidelines specifically for NIPD,
we can develop a practice that will permit NIPD to significantly enhance a
pregnant woman's reproductive autonomy.
3. Two Step Consent Proposal
One possible solution is to require a two-step process for NIPD informed
consent-one appointment for counseling followed by a second for decision-
making and testing. 279 In van den Heuvel et al.'s survey, 94 percent of
practitioners preferred patients to receive the offer and test on different days
for IPD, whereas 74 percent preferred a two-step approach for NIPD and
DSS. 280 Separating the offer and discussion of NIPD from the testing
procedure differentiates NIPD from other routine laboratory tests given to a
pregnant woman on her first prenatal visit and signifies the importance of
276. Benn & Chapman, supra note 94, at 2154.
277. Id. at 2155.
278. de Jong et al., supra note 80, at 275.
279. Schmitz et al., supra note 180, at 733.
280. van den Heuvel et al., supra note 231, at 27.
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thinking through the decision to engage in prenatal diagnostic testing. In a
two-step approach, health care providers would first give patients
information on the reliability of NIPD testing and the conditions tested for,
then patients could take the information home, read it over, discuss it with
the others close to them, and think through their values and preferences. At
the second appointment, patients could ask any questions they had, discuss
their thoughts with the practitioner, and decide whether to have the test. To
expedite the process, the second appointment could be via telephone if the
patient desired and afterward the physician could call the tests into the most
convenient lab for the patient to have her blood drawn. The two-step process
guarantees that the patient knows in advance that she is electing to undergo
diagnostic prenatal testing and requires affirmative action by her to schedule
and return for the testing. It also provides her with an opportunity to examine
the information outside of the physician's presence and to discuss the
decision with her spouse, family, or other interested parties.
A two-step approach raises some theoretical and practical challenges.
Theoretically, providing patients with additional time to consider genetic
testing may not produce more informed results and requiring two
appointments may hinder access to desired treatment. Empirical evidence on
the effectiveness of a two-step model is sparse. In the prenatal context, no
empirical evidence exists to support or refute the assumption that providing
281patients with additional time for reflection facilitates informed choice.
While performing IPD counseling and testing on same day has been
associated with higher rates of uptake, this practice has not been shown to be
associated with making less informed decisions.282 These findings may
suggest that a two-step approach would reduce uptake without improving
patient decision-making. However, these studies are very limited in number
and scope and have not examined single step counseling in the context of
NIPD. Other studies performed on the use of shared decision-making and
clinical decision aids, which typically require a two-step approach,
281. van den Heuvel et al., supra note 231, at 27.
282. Id.; Robert P. Lorenz et al., Encouraging Patients to Undergo Prenatal Genetic
Counseling Before the Day of Amniocentesis: Its Effect On the Use of Amniocentesis, 30 J.
REPRODUCTIVE MED. 933 (1985). One observational study even found that patients who
received same day counseling and testing made more informed choices than those who
separated counseling and testing, but this finding was not replicable in experimental testing. E.
Dormandy et al., Informed Choice to Undergo Prenatal Screening: A Comparison of Two
Hospitals Conducting Testing Either As Part of a Routine Visit or Requiring a Separate Visit,
9 J. MED. SCREEN 109, 109 (2002); E. Dormandy et al., Informed Choice in Antenatal Down
syndrome Screening: A Cluster-Randomized Trial of Combined Versus Separate Visit Testing,
61 PATIENT EDUC. & COUNSELING 56, 56 (2006).
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demonstrate improvement in the patient's knowledge and understanding of
the decision and reductions in their decisional conflict.283 In these studies,
patients receive decision aids to take home and review with others prior to
the meeting with their physician where the treatment decision is made.
Clinical research is needed to determine the impact of a two-step consent
process on the ability of individuals to make an informed choice regarding
NIPD. Until the empirical research demonstrates that a single step approach
provides similar levels of informed decision making and patient satisfaction,
clinicians should err on the side of providing patients with more time for
reflection and discussion.
Practically, a two-step approach creates more work for both provider and
patient. Providers may have significant difficulty scheduling separate visits
for information and decision-making for all of their prenatal patients.
However, the use of phone appointments and nurse practitioners may help
alleviate scheduling challenges. Secondly, providing the full extent of
information required to enable a patient to make an informed decision
regarding diagnostic genetic testing for a wide range of conditions will be
nearly impossible to compile, let alone convey in an office visit, or even in
an book of materials to take home. Patients are unlikely to read all of the
relevant information on all genetic tests, even with extra time, and may still
end up making uninformed decisions. A two-step informed consent process
will offer women a chance to think through their decisions and ensures that
they do not unwittingly undergo NIPD, but it will not remedy the sheer
information burden associated with obtaining informed consent for NIPD for
a wide range of conditions.
283. Annette O'Connor et al., Decision Aids for People Facing Health Treatment or
Screening Decisions, THE COCHRANE LIBRARY, no. 1, 2004. Of the 131 available decision aids
examined in the meta-analysis, most were designed for use prior to counseling from a
physician. Across the 131 trials decision aids for a variety of screening and treatment
decisions, patients who used decision aids rather than usual care demonstrated: 1) greater
knowledge; 2) more realistic expectations; 3) lower decision conflict; 4) increased patient
activation; and 5) a smaller percentage of individuals undecided. Id. These findings were
reconfirmed in the updated systematic review in 2009. Annette O'Connor et al., Decision Aids
for People Facing Health Treatment or Screening Decisions, COCHRANE DATABASE OF
SYSTEMATIC REVIEWS, no. 3, July 8, 2009, available at http://www2.cochrane.org
/reviews/en/abOO1431 .html [hereinafter O'Connor et al., Decision Aids 2009].
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C. Proposal for NIPD Testing Panels and Corresponding Decision Aids
To remedy challenges in selection of genetic tests appropriate for NIPD
and informed consent, clinicians could offer NIPD in standardized panels
that the patient selects based on their personal values and informational
needs. Professional societies, such as the American College of Obstetricians
and Gynecologists (ACOG), the National Society of Genetic Counselors
(NSGC), and the American College of Medical Geneticists (ACMG) (the
Professional Societies), with input from leading stakeholder groups should
design testing panels appropriate for NIPD. Testing panels should be based
on salient disease characteristics, in order to simplify informed consent for
approved applications of NIPD.284 For instance, inclusion of a test for a
particular genetic condition on a panel should depend on the analytic
validity, clinical validity, and clinical utility of the test, as well as
characteristics of the condition, including age of onset, average life
expectancy, severity of the symptoms, available treatment, and range of
variation in symptoms. Different panels could exist to test for severe diseases
with low life expectancy, diseases with significant cognitive and physical
deficits and no treatment, diseases with significant cognitive and physical
deficits and treatment, late onset disorders, predispositions to disease, and
non-medical conditions, such as sex and other physical traits.
While diseases within each category will differ significantly from one
another, many of the considerations for prospective parents may not. The
distinctions between standard panels should highlight factors that have value
for large portions of the population. For example, some parents may want to
test for only those conditions that typically result in death before the age of
five, where as others will want to test for serious mental and physical
conditions, but not late onset diseases. Still others will want access to all
available information. Standardizing panels will permit prospective parents
to determine what kind of information they value and obtain only that kind of
information. At the same time, standardized panels will permit genetic
counselors to focus on the implications of certain categories of disorders in
predictable ways, while avoiding having to discuss the implications of
potentially hundreds of diseases and conditions.
In an effort to remedy the lack of genetic counseling resources, patient
decision aids could be used to standardize the initial offer of information
284. 1 do not recommend that Professional Societies determine what tests are available
to the public, but that for those approved tests, they create approved panels of tests based on
their salient characteristics.
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regarding the various panels of tests available. Decision aids are videos and
reading materials designed to convey standardized information regarding a
medical decision to patients in an accessible manner.285 Decision aids for
NIPD panels would include detailed descriptions and salient features of the
kinds of diseases tested for on a particular panel. Decision aids could also
provide information from genetic counselors using a variety of methods to
explain genetic risk information, and the possibilities of false positives and
false negatives. In addition, these aids could present a range of values
implicated by prenatal testing and in doing so offer an opportunity to change
the discussion regarding having a child with a genetic disorder or disability
on a national level.286 They could include information on families living with
a disabled child and their overall quality of life. Decision aids can prompt
patients to consider their personal values with respect to prenatal genetic
testing, including the kind of information they would want to know, and how
they would use it. Patient decision aids often have patient testimonials that
may help patients identify their own values or questions they may wish to
discuss with their physician, family members, or other individuals with
similarly affected children. After viewing the decision aid, patients who were
still interested in receiving NIPD would have a follow up appointment or
phone call with their provider to discuss the risks and benefits of testing for
various panels. After an individualized protocol of panels has been selected
and the provider answered any remaining questions, the woman would sign
an informed consent form and go to the lab for testing.
This two-step consent/panel approach raises significant challenges. First,
determining which tests should be on which panel will require difficult line
drawing tasks. Placing a particular test on the severe disorders panel may
send a message to prospective parents that there is an expectation that if their
fetus tests positive for that disorder, they would abort. Whereas, if the same
disorder were placed on the moderate physical or mental impairment panel,
prospective parents may not feel the same pressure. Likewise, identifying
certain disorders as severe for prenatal testing purposes may send the
message that society does not value their lives as much as others. 287 As a
result, the language used as part of the informed consent process must be
very carefully crafted to avoid sending either of these messages. In many
285. O'Connor et al., Decision Aids 2009, supra note 283.
286. For a more in depth discussion of the use of prenatal testing as an opportunity to
reframe the existing discussion about disability, see Elizabeth Emens, Framing Disability,
(draft on file with author).
287. Erik Parens & Adrienne Asch, The Disability Rights Critique of Prenatal Genetic
Testing: Reflections and Recommendations, 29 HASTINGS CENTER REP. S1, SI -2 (1999).
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respects, creating decision aids may help standardize the message patients
receive regarding living with disorders of this type and the fact that the
decision to have an affected child remains a viable and socially supported
option. Second, if not carefully tested prior to commercial use, decision aids
may inadvertently bias patient decisions. 288 As with all decision aids, a
national agency should be responsible for overseeing the creation of decision
aids used for NIPD and testing them through clinical trials to ensure that they
present all options, especially the option not to test, in a balanced manner.
Finally, the use of testing panels may constrain the reproductive autonomy of
prospective parents by forcing them to test for diseases and receive genetic
information, which they otherwise would not want.289 Two potential
solutions exist. Providers can offer prospective parents the choice between a
predetermined panel and an individualized set of genetic tests, which may
cost significantly more. Alternatively, providers could permit patients to
select the tests on the panel that they would like to see the results for and
keep the results for the remaining tests confidential. 290 While this two-
step/panel model presents some challenges, if the challenges are addressed
properly, the benefits appear to outweigh the risks.
A two-step decision-making process that uses decision aids designed for
predetermined panels of genetic tests based on similar characteristics
accurately highlights the importance of the decision to engage in prenatal
diagnostic testing, sends the message that testing is neither expected nor
routine, promotes thoughtful reflection by patients, and limits the time and
expense required to adequately inform patients. While such a process does
not address all of the concerns with patient understanding and consent for
NIPD, it will greatly improve the patient's chances of making an informed
decision to engage in NIPD over existing prenatal genetic testing informed
consent procedures.
288. King & Moulton, supra note 229, at 490.
289. At the 2011 American Association of Law Schools Annual Meeting, Gaia
Bernstein raised this criticism of genetic testing services like 23&Me and Counsyl, which
offer testing for a range of conditions at once, but do not permit patients to individualize their
testing. Gaia Bernstein, Professor of Law, Seton Hall University School of Law, Genetic
Testing, Presented at THE ASSOCIATION OF AMERICAN LAW SCHOOLS ANNUAL MEETING (Jan.
6,2011).
290. The latter approach raises significant ethical challenges, which are outside the
scope of this paper, but should be explored in depth prior to implementing this model.
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IV. FUTURE SOCIETAL CHALLENGES FROM WIDESPREAD NIPD USE
As NIPD is introduced into prenatal care, we should consider what
widespread NIPD use may mean for society as a whole. While NIPD will
offer significant scientific improvements over current prenatal and
preimplantation genetic testing techniques, does such testing raise any new
questions regarding reproductive genetic testing in general? No, not really.
For the last two decades, legal and ethical scholars have argued over what
advances in reproductive genetic selection mean about our attitudes toward
individuals living with disorders being screened for, the limits of individual
reproductive autonomy, and the legal status of the embryo. 29 In general,
most argue that while reproductive genetic testing offers significant benefits,
its unconstrained use portends worsening of societal ills, including increased
discrimination against individuals with undesirable genetic conditions,
further socioeconomic stratification, and diminished autonomy with respect
291. See, e.g., King, supra note 88; Sonia M. Suter, A Brave New World of Designer
Babies?, 22 BERKELEY TECH L.J. 898, 922 (2007); FRANCIS FUKUYAMA & FRANCO FURGER,
BEYOND BIOETHICS: A PROPOSAL FOR MODERNIZING THE REGULATION OF HUMAN
BIOTECHNOLOGIES 293-300 (2006); June Carbone & Paige Gottheim, Markets, Subsidies,
Regulation, and Trust: Building Ethical Understandings into the Market for Fertility Services,
9 J. GENDER, RACE & JUST. 509 (2006); Michael J. Sandel, The Case Against Perfection, 293
ATLANTIC MONTHLY 51 (2004); Rao, supra note 144, at 1457; JOHN A. ROBERTSON, CHILDREN
OF CHOICE (Princeton University Press 1994); John A. Robertson, Genetic Selection of
Offspring Characteristics, 76 B.U. L. REV. 421 (1996); Alexander N. Hecht, The Wild Wild
West: Inadequate Regulation of Assisted Reproductive Technology, 1 HOUS. J. HEALTH L. &
POL'Y 227 (2001); Michael J. Malinowski, Choosing the Genetic Makeup of Children: Our
Eugenics Past - Present, and Future?, 36 CONN. L. REV. 125 (2003); Michael J. Malinowski,
A Law-Policy Proposal To Know Where Babies Come from During the Reproduction
Revolution, 9 J. GENDER, RACE & JUST. 549 (2006) ; Lars Noah, Assisted Reproductive
Technologies and the Pitfalls of Unregulated Biomedical Innovation, 55 FLA. L. REV. 603
(2003); Adrienne Asch, Why I Haven 't Changed My Mind About Prenatal Diagnosis:
Reflections and Refinements, in PRENATAL TESTING AND DISABILITY RIGHTS 234 (Erik Parens
& Adrienne Asch eds., 2000); Vicki G. Norton, Unnatural Selection: Nontherapeutic Pre-
implantation Genetic Screening and Proposed Regulation, 41 UCLA L. REV. 1581 (1994);
Erik Patens & Lori P. Knowles, Reprogenetics and Public Policy: Reflections and
Recommendations, 33 HASTINGS CENTER REP. S1 (2003); Jennifer L. Rosato, The Children of
ART (Assisted Reproductive Technology): Can the Law Protect Them from Harm?, 2004
UTAH L. REV. 57 (2004); Lindsey A. Vacco, Pre-implantation Genetic Diagnosis: From
Preventing Genetic Disease to Customizing Children. Can the Technology Be Regulated
Based on the Parents'Intent?, 49 ST. LOUIS L. J. 1181 (2005); Aaron R. Fahrenkrog, Note, A
Comparison of International Regulation of Pre-implantation Genetic Diagnosis and a
Regulatory Suggestion for the United States, 15 TRANSNAT'L L. & CONTEMP. PROBS. 757
(2006); Note, Guiding Regulatory Reform in Reproduction and Genetics, 120 HARV. L. REV.
574 (2006).
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to reproductive choices. With NIPD, the substance of these issues remains
the same, however, implementing NIPD into standard prenatal care, such that
someday physicians might offer every pregnant woman a risk-free way to
find out a great deal about her fetus' genotype at a very early point in the
pregnancy, warrants serious reconsideration of these arguments. For the
remainder of the article, I will briefly highlight some of the concerns
resurfaced and expanded by routine NIPD use, which I hope will spur further
discussion, research and writing in this area.
292
Society as a whole should consider the social consequences of making
NIPD for specific conditions part of standard prenatal practice. A routine
offer of testing can send a message to patients that the physician views
testing as a good idea and recommends it for a specific condition.293 In
addition, a routine offer of testing for a particular condition may also convey
a belief that testing positive for such a condition justifies termination of a
fetus. Indeed, the term "therapeutic abortion" conveys the idea that
terminating the fetus is the "treatment" for its condition.294 On a national
scale, normalizing the offer of NIPD to all pregnant women can create
significant pressure on women both to test their fetuses and terminate
affected fetuses, as the information is easily available via a risk free
medium. 295 This pressure can create a loop-back effect, such that the ease of
testing and termination create disapproval for and reduction in support of
women with disabled children, which, in turn, may increase the pressure to
test.296 The message may easily be distorted. For instance, Counsyl's website
posts a quote from Steven Pinker, a professor from Harvard University,
stating that "universal genetic testing can drastically reduce the incidence of
genetic diseases, and may very well eliminate them entirely. 2 97 The website
also claims "while these [genetic] diseases cannot be cured, with the
Universal Genetic Test they can now be prevented. The test is recommended
to be offered to both men and women and tests for diseases common to every
ethnic group, for maximum safety., 298 Of course, the company fails to
acknowledge that its test does not prevent the occurrence of a genetic
292. 1 do not intend to begin to address any of these topics in the appropriate depth.
My goal for this last section is to raise topics for future thought and discussion that I think are
important issues with respect to the long-term implementation of NIPD.
293. Suter, supra note 125, at 241; de Jong et al., supra note 80, at 273.
294. Suter, supra note 125, at 266.
295. Schmitz et al., supra note 180, at 733.
296. Hall et al., supra note 102, at 249-50; van den Heuvel et al., supra note 231, at
28.
297. What People Are Saying, COUNSYL.COM, supra note 215.
298. Introducing the Universal Genetic Test, COUNSYL.COM, supra note 215.
[Vol. 42:599
AND GENETIC TESTING FOR ALL
disease, instead it prevents the birth of the person with the genetic disease.
Seeking to "prevent" the birth of individuals with undesirable genetic traits is
reminiscent of the eugenic goals of the early twentieth century. 299 Without
significant thought and guidance, individual physicians and biotechnology
companies may broaden the scope of reproductive genetic testing and
selective termination without adequate consideration for the message sent to
prospective parents or the social consequences of their collective action.
Routinizing NIPD into standard prenatal care creates the opportunity for
collective individual parental decision-making to change the constitution of
society. Francis Fukuyama and Franco Fuger have argued that widespread
use of reproductive genetic selection could lead to increased inequality
resulting in a wide division between the "haves" and the "have nots.,, 300 For
instance, if private health insurance pays for NIPD, but Medicaid does not,
this has the potential to accelerate the division. Further, Erik Parens and
Adrienne Asch have argued that prenatal genetic testing and therapeutic
abortion have the potential to negatively affect the way society perceives and
treats individuals with undesirable genetic disorders and conditions.3°0
Specifically, unfettered NIPD use has the capacity to lead to significantly
more abortions of fetuses identified with certain genetic conditions and more
abortions of fetuses for conditions currently not tested for prenatally.30 2 But it
does not have to.
We should ensure that the option to have a child with a genetic disorder
remains a meaningful option. Whether this remains a reality will depend
largely on the information pregnant women are given about NIPD and how it
is framed.30 3 The offer of NIPD not only represents an opportunity to help
women make a decision regarding their own pregnancy, but it also represents
an opportunity to educate a large portion of the population about the realities
and positive aspects of the lives of individuals and families living with
genetic disorders and disabilities. As a society, we must dedicate ourselves to
offering comprehensive support services for families affected by a genetic
disorder and to communicating the availability of those opportunities to
parents who have recently had a fetus diagnosed with such a disorder.
Significant barriers should be put in place to counteract the pressure to test
and selectively abort affected fetuses that pregnant women may experience
299. Judith F. Daar, ART and the Search for Perfectionism: On Selecting Gender,
Genes and Gametes, 9 GENDER, RACE & JUST. 241, 260-61 (2005).
300. FUKUYAMA & FURGER, supra note 291, at 293-300.
301. Parens & Asch, supra note 287, at Si -2.
302. Schmitz et al., supra note 180, at 733.
303. See generally Emens, supra note 286.
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with respect to NIPD. The only way for NIPD to enhance prospective
parents' reproductive autonomy is for it to truly broaden the options
available to parents, rather than constrain them through increased social
discrimination. Our ability to prevent the societal harms possible from
widespread NIPD use will be determined by the actions we take from the
outset to minimize the hardships associated with living in society with
certain genetic conditions, monitor the collective decision making of
individuals in society, and determine our overall societal goals associated
with the use of NIPD.
Widespread NIPD may also cause us to reexamine states' abilities to
restrict the free exercise of individual reproductive autonomy. If a woman
can abort a fetus because she does not want any child, does the constitutional
protection that affords her that choice extend to protect her ability to decide
to abort a fetus for any specific genetic reason, even if the condition in
question posed no or minimal clinical symptoms? We must consider whether
reproductive liberty should protect the right of a woman to terminate a fetus
because she does not want a child with a specific hair or eye color, or a
predisposition to certain behavioral traits. Genetic testing companies will
offer prospective parents this information, and many will accept. A recent
study performed at New York University Medical Center found that around
10 percent of patients surveyed at the NYU Human Genetics Program for
prenatal genetic testing would test for genes associated with non-medical
traits such as longevity, superior intelligence, superior athletic ability, or
height if they were available.30 "
In the interest of protecting unborn fetal life, states may attempt to
restrict a woman's ability to abort based on information she discovered
through NIPD. In fact, a handful of states have recently passed legislation
restricting providers' ability to abort a fetus when he or she knows that the
woman seeks the abortion based on the sex of the fetus.30 5 The Arizona state
legislature recently expanded the abortion prohibition to make it a class 3
felony to provide an abortion sought on the basis of the race or sex of the
fetus. 30 6 These kinds of laws have significant practical and theoretical
304. Feighanne Hathaway, Esther Bums & Harry Ostrer, Consumers' Desire Towards
Current and Prospective Reproductive Genetic Testing, 18 J. GENETIC COUNSELING, 137, 137-
46 (2009).
305. 18 PA. CONS. STAT. ANN, § 3204(c) (West 2000); 720 ILL. COMP. STAT. ANN. 510
/6(8) (West 2003); H.B. 1595, 52nd Leg., 1st Sess. (Ok. 2009).
306. 2011 Ariz. Legis. Serv. Ch. 9 (West); Steven Ertelt, Arizona: Brewer Signs Ban
on Sex-Selection, Race-Based Abortions, LIFENEWS.COM (Mar. 30, 2011, 1:14 PM),
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problems. Practically, they will be nearly impossible to enforce. Women
seeking abortions for reasons of race or gender will be unlikely to reveal
their reasoning to their provider. Theoretically, after a woman has undergone
prenatal testing and discovered that her fetus has a genetic condition she does
not want, a state may face significant constitutional challenges in forcing her
to bear a child she does not want.
30 7
But that is not the end of the story. A more serious challenge is whether a
state can restrict the kinds of genetic tests available through NIPD for
prenatal decision-making. If state governments cannot regulate a woman's
ability to have an abortion for a specific reason, they may seek to regulate
what prenatal and preimplantation tests a woman can have prior to viability
to prevent parents from discarding fetuses for reasons the state deems not
essential to reproductive autonomy. As a society, we will need to consider
how to best balance an individual's desire to access all scientifically
available information with the interest of a state to protect fetuses from being
destroyed for trivial reasons.0 8 Regulating access to these tests will not be
easy. Many tests, such as fetal sex determination, serve both medical and
non-medical purposes. And, as mentioned above, drawing lines regarding
which tests are appropriate for NIPD use may negatively impact individuals
living in society with the conditions for which screening will be available.
Answering these questions will be challenging, but we must take the
opportunity to consider the societal implications of widespread NIPD use,
what kind of society we wish to live in, and how far to extend reproductive
liberty. Many of these questions have been explored in depth in relation to
other forms of reproductive genetic testing, but NIPD has the ability to affect
the reproductive decision-making at a societal level making it imperative to
reconsider these debates in the context of widespread NIPD.
http://www.lifenews.com/2011/03/30/arizona-brewer-signs-ban-on-sex-selection-race-based-
abortions/?pr= 1.
307. A detailed analysis of the constitutional challenges surrounding a state's ability to
regulate access to abortion or reproductive genetic testing is outside the scope of this article.
For such a description, see Sonia M. Suter, The "Repugnance" Lens of Gonzales v. Carhart
and Other Theories of Reproductive Rights: Evaluating Advanced Reproductive Technologies,
76 GEO. WASH. L. REV. 1514, 1576 (2008); Radhika Rao, Reconceiving Privacy:
Relationships and Reproductive Technology, 45 UCLA L. REV. 1077, 1078 (1998).
308. 1 take up this issue in significantly more depth in a forthcoming article. Jaime S.
King, Not this Child: Constitutional Questions in Regulating Non-invasive Prenatal Genetic
Diagnosis and Selective Abortion, 60 UCLA L. REV. _ (forthcoming 2012).
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V. CONCLUSION
NIPD is coming, faster than our ability to fully consider the ethical, legal
and social consequences of its use. Without question, NIPD offers
prospective parents previously unimaginable benefits. Parents will have more
knowledge about their fetus than ever before. Every year in the U.S., NIPD
will prevent hundreds of women with wanted pregnancies from miscarriage
caused by amniocentesis or CVS. 3°9 Prospective parents will avoid
unnecessary treatment for diseases like RhD incompatibility, and be able to
treat other genetic conditions while the fetus is still in utero or immediately
upon birth. However, more than any advance in reproductive genetic testing,
NIPD has the potential to dramatically change not only prenatal care, but
also the way prospective parents think about their potential children. If
offering NIPD testing for a wide range of conditions becomes the standard of
care such that it is offered to a substantial number of pregnant women early
in their pregnancy, prospective parents may view each pregnancy as
"contingent" awaiting NIPD test results. We must take this brief moment to
consider both the initial implementation challenges raised by NIPD, as well
as the broader societal implications of its use. We have the chance to change
our thinking about prenatal testing and the way it is presented to pregnant
women. But such presentation must be done by careful design. Providers will
need significant guidance and information on which tests to offer and how to
best inform patients prior to engaging in NIPD. A two-step approach to
informed consent that employs the use of decision aids and test panels
created based on the salient characteristics of the underlying genetic
conditions may significantly alleviate challenges faced in test selection and
information transfer with patients. With respect to the broader social
concerns, I have raised a number of potential issues in hopes of stimulating a
societal conversation regarding the appropriate bounds of regulation and use
of prenatal genetic testing in the future. I look forward to continuing to
participate in this conversation as NIPD continues to enter the market.
309. ABCNEWS.GO.COM, supra note 101.
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